Temoporfin (Foscan®, 5,10,15,20-Tetra(m-hydroxyphenyl)chlorin)—A Second-generation Photosensitizer

Authors

  • Mathias O. Senge,

    Corresponding author
    1. Medicinal Chemistry, Institute of Molecular Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, St. James’s Hospital, Dublin 8, Ireland
    2. SFI Tetrapyrrole Laboratory, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland
    Search for more papers by this author
  • Johan C. Brandt

    1. SFI Tetrapyrrole Laboratory, School of Chemistry, Trinity College Dublin, Dublin 2, Ireland
    Search for more papers by this author

  • Lead Structures for Applications in Photodynamic Therapy. Part 3.

  • Dedicated to Professor Ray Bonnett.

Corresponding author email: sengem@tcd.ie (M. O. Senge)

Abstract

This review traces the development and study of the second-generation photosensitizer 5,10,15,20-tetra(m-hydroxyphenyl)chlorin through to its acceptance and clinical use in modern photodynamic (cancer) therapy. The literature has been covered up to early 2011.

Introduction

The field of photodynamic therapy (PDT) (1) has seen continuous advances in the past decades. Modern studies began with investigations on haematoporphyrin (Hp) (2). To some extent the progress made can be traced along the lines of the different types of photosensitizers (PS) which have been developed. Typically, the various PS used in PDT are termed as first-, second- and third-generation PS (3). The first generation is basically Hp derivative (HpD) which was approved as Photofrin for clinical use in 1993 (4), the second generation are simple, chemically pure and defined PS (e.g. Foscan) (5) and the third generation are systems currently in development which contain specific targeting groups or have been developed based on clear medical, photophysical and chemical design principles (6).

Broadly speaking, the properties for an ideal photosensitizer are: chemical purity, high quantum yield of singlet oxygen production, significant absorption in the long wavelength region (700–800 nm), preferential tumor localization, minimal dark toxicity and delayed phototoxicity, stability and easy to dissolve in the injectable solvents (formulation). While Photofrin is an effective photosensitizer, its shortcomings could not be neglected. This gave rise to the development of chemically pure PS with optimized photophysical properties. This so-called second-generation PS have entered a lively competition during the last decade to the benefit of both science and the patients (7–9). This is related not only to the use as a photosensitizing drug for treatment but for the use in photodiagnostics (PD) and imaging as well (10). Within this second generation, porphyrins are the most widely investigated class of compounds and it is generally assumed that these macrocycles and their reduced derivatives such as chlorins and bacteriochlorins are the most suitable candidates for PS drug development (11–17).

5,10,15,20-Tetra(m-hydroxyphenyl)chlorin (mTHPC, 1) with the generic name “Temoporfin” and the proprietary name “Foscan®” is one of these promising reduced porphyrins which has been the subject of investigations by a number of research groups for almost two decades. Now, Temoporfin has reached an exciting state of development as it has gone through the requisite clinical testing and is regarded as an established cancer drug on the market. It can thus serve as an illuminating show and test case for the potentials and limitations of current PDT drugs and might give an insight into the trends of development for the new generation of PS. This review intends to discuss the published works of mTHPC with the intention of: summarizing the available facts and discussing mTHPC’s potential continuation; comparing known properties with the required attributes for an ideally designed photosensitizer; if possible, delineating novel design and application principles from the biochemical and clinical results obtained with mTHPC. For ease of argument, unless expressively stated otherwise, in the following “PS,”“drug,” etc. relates to mTHPC.

Many general PDT reviews have appeared over the years. They are too numerous to list here and often their content overlaps. Likewise, a multitude of brief reviews on individual cancer types or PDT applications can be found; those that add to the context of this treatise are listed in the individual subsections. Next to historical reviews (18–21), Bonnett’s book on Chemical Aspects of Photodynamic Therapy (3) is still a good entry into the field for medicinal chemistry students, as are classic reviews by Dougherty and Kessel (4,18,22–24) and more chemically oriented treatises (25). A more recent three part series on the basics of PDT by Castano et al. from 2004 is recommended for an entry into the field especially for students (26–28).

Chemistry and development of temoporfin

Synthesis, characterization and detection

In the mid-1980s Bonnett et al. undertook a significant screening procedure (biophysically, biochemically and pharmacologically) of a library of porphyrins for the purpose of discovering an effective second-generation photosensitizer (29). They decided on the tetra(hydroxyphenyl)porphyrins as the most promising compounds after initial tests with their porphyrin analogs revealed a 25–30 times enhancement in photosensitization compared to HpD in tumor models (30) and gave superior tumor localization in C3H mice (31). After thoroughly comparing the essential properties of the ortho, meta and para phenyl isomers (32) a similar necrosis depth was noted for the m,p compounds, while the ortho isomer resulted in higher skin sensitivity. Overall, the meta isomer was the best in terms of cost and benefits (Fig. 1). The only significant drawback of these porphyrins was their weak absorption in the area of 630 nm which meant nothing was gained in this regard compared to Photofrin®. Nevertheless, a number of in vitro and in vivo tests established the basic PDT properties and advantage of the mTHPP porphyrin (33–41).

Figure 1.

 Chemical formulas of compounds of the 5,10,15,20-tetra (m-hydroxyphenyl)porphyrin series: (1), the chlorin, a dihydroporphyrin, mTHPC; (2), the parent porphyrin, mTHPP; (3), the bacteriochlorin, a tetrahydroporphyrin, mTHPBC.

To improve the absorption properties, chlorin analogs of these hydroxyphenylporphyrins were synthesized via a diimide reduction (42). This reduction step was introduced to gain a more intense and more redshifted absorption band to allow deeper penetration into tissue. The chlorin 5,10,15,20-mTHPC, 1 was derived from the parent porphyrin (5,10,15,20-tetra(m-hydroxyphenyl)porphyrin) (mTHPP, 2) and showed effective induction of necrosis in tumor tissue in PC6 tumor inoculated mice with less muscular edema than in other PDT compounds. This project was the first successful attempt at a methodical approach to synthetically optimize the absorption characteristics of tetrapyrrolic PS for PDT. Formally, the synthesis of mTHPC involves the acid-catalyzed condensation of pyrrole with m-hydroxy benzaldehyde to yield the porphyrinogen, followed by oxidation to mTHPP and then reduction to mTHPC.

In many regards mTHPC fits many of the requirements specified above for an ideal photosensitizer, and thus may be regarded to be “better” than Photofrin (43,44). It can be prepared as a chemically pure compound, it shows enrichment in tumor versus normal tissue and has an absorption maximum at 650 nm, redshifted compared to HpD which means deeper light penetration. In addition, mTHPC requires smaller quantities for administration, shorter treatment times and a lower light dose to achieve the desired PDT response (45).

Briefly, its industrial development proceeded as follows. Initially, a UK biopharmaceutical company (Scotia Pharmaceuticals Ltd., UK) developed the drug, first in collaboration with Boehringer Ingelheim and in 1999 was granted orphan drug status by the U.S. Food and Drug Administration (FDA) and was accepted for marketing review by the European Medicines Evaluation Agency (EMEA). In 2000, it was granted fast track review status by the FDA. Nevertheless, approval by the FDA was declined in September 2000, and then in January 2001 by the EMEA. As a result, Scotia Holdings plc. had to go into administration. Scotia was one of Britain’s oldest biotech companies and at its height in 1997 had a market value of £500 million. Nevertheless, an appeal to the EMEA was successful in June 2001 and later in 2001 marketing authorization was given as a local therapy for the palliative treatment of patients with advanced head and neck cancer who have failed prior therapies and are unsuitable for radiotherapy, surgery or systemic chemotherapy. Financially, this did not save Scotia, which, renamed as Quantanova, was sold to the German Biolitec AG in April 2002. Since then, Biolitec Pharma distributes the drug and investigates further uses.

After mTHPC was recognized as a potential PS analytical investigations were undertaken to obtain detailed knowledge of the compounds properties. The fine structures in the 1H-, 13C- and 15N-NMR spectra have been clarified (46) and mass spectrometric studies undertaken (47). To enable research into kinetic phenomena of the radical Type I mechanism, ESR experiments observing mTHPC with and without stable free radicals (e.g. di-tert-butyl nitroxide) have been undertaken (48). A suite of photophysical measurements were performed on the o-, m- and p-tetra(hydroxyphenyl)porphyrins in 1988 by Bonnett et al. including fluorescence, flash photolysis and pulse radiolysis studies in order to characterize the singlet and triplet excited states of these macrocycles (49). A comparative study including the reduced derivatives mTHPC and the bacteriochlorin analog (mTHPBC, 3) was performed in 1999 (50). The absorption maximum of the long wavelength absorption band is shifted from 644 in the porphyrin to 650 nm in the chlorin and 735 nm in the bacteriochlorin. Photophysical properties of the first excited state were similar in all three compounds and the quantum yield for singlet oxygen formation was 0.43–0.46 in aerated methanol.

A study of the absorption and emission dependence upon pH was also done for mTHPC, mTHPP and other PS (51). Within the physiological pH range 6.5–7.2 no pH dependence of the fluorescence intensity was found. Only below pH 6 a significant loss of intensity was observed (52). The dynamics of the excited states of mTHPC have been investigated in time-resolved studies on the fs to μs time scales (53). The lifetime of the singlet state was found to be longer for mTHPC compared to other PS, which might be one of the reasons for its high efficacy as a PS. Experiments within the cytoplasm of cells later revealed a decrease of this lifetime from 7.5 to 5.5 ns which was attributed to aggregation in the biological environment (54). Resonance light scattering experiments showed the formation of J-aggregates for mTHPC in aqueous solution (55,56).

The acid–base properties of mTHPC were analyzed by Bonnett et al. (57). Spectrophotometric titration of the photosensitizer in a methanol/buffer mixture gave pK3 and pK4 values of 3.45 and 1.45, respectively, while the phenolic groups exhibited a pKa of 10. They also investigated the singlet oxygen production from mTHPC through the photobleaching of bilirubin, which was accelerated five-fold in the presence of a catalytic amount (5 mol%) of the PS, but hindered in the presence of the singlet oxygen quenchers, β-carotene and 2,5-dimethylfuran. A comparative analysis of the pH-dependent properties showed that only mTHPP but not mTHPC changed lipophilicity in the pH range 4–8 (58).

The analytical detection of PS in biological material is a challenging topic. Detection of mTHPC in human plasma following infusion was carried out successfully via reverse-phase HPLC-UV detection with a sensitivity of 15 ng mL−1 (59). This method was then extended to mouse, rat and human tissue (60). Using coloumetric detection, Barberi-Heyob et al. improved the sensitivity for detecting mTHPC in plasma to as low as 5 ng mL−1 (61). A similar detection could also be achieved using an improved HPLC fluorescence detection method (62). Formation of a 1:2 cyclodextrin:mTHPC complex resulted in an up to 300 times enhanced fluorescence signal (63) and could be used for detection in human plasma (64). Similar results were later reported for 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin (65). Two-step laser MS was used as a qualitative analytical tool to study PS purity (66). There is also significant variability in the fluorescence properties depending on the tissue and PS type. Tissue relevant fluorescence excitation-emission matrices have been collected to aid in the analysis (67). Dynamic capillaroscopy has been used as a means to evaluate pharmacokinetics in vivo (68,69).

Photobleaching

One of the most important questions regarding the use of a PS relates to its photostability. Porphyrins typically undergo slow photodegradation with time. The importance of the phenomenon of photobleaching, i.e. the irreversible photodestruction of the pigment, for PDT has been recognized as a potential means to control both the pharmacokinetics of the drug and the occurrence of undesired side-effects. However, the balance of photobleaching versus photoaction is delicate, for if the sensitizer bleaches too rapidly, tumor destruction will not be complete. However, with appropriate knowledge of bleaching rates and drug dosage, light damage to normal tissue at the treated site may be reduced due to controlled minimized sensitizer concentrations in these areas. Another plausible application of photobleaching is the elimination of the drug, consequently reducing postoperative skin photosensitivity, which is the main adverse effect patients experience when undergoing PDT.

Initially, Bonnett et al. examined in a comparative study the photobleaching properties of methanolic solutions of mTHPC, mTHPP and mTHPBC (70). mTHPC and mTHPBC were subject to pronounced photodegradation following laser irradiation at 514 nm, while mTHPP resulted in the formation of quinoid porphyrins (70,71). The photophysical impact on mTHPP is less pronounced than for either reduced analog, but the rapid degradation of mTHPBC precludes a practical use in PDT. An analysis of the degradation of these sensitizers via NMR, UV and MS showed the photoproducts largely to consist of benzoquinone isomers (4), dihydroxyphenyl derivatives (5) and ring-opened chains followed by further breakdown to methyl 3-hydroxybenzoate, succinimide and maleimide (Fig. 2).

Figure 2.

 Photobleaching products of mTPHC derivatives.

Recent results indicate the rate of photobleaching of mTHPBC to be strongly dependent on the degree of aggregation of the PS (72). A combined use of HPLC and electrospray ionization tandem MS (ESI-MS) identified mTHPP and several hydroxylated derivatives of both mTHPC and mTHPP as initial photobleaching products (73). Angotti et al. found evidence for both Type I and Type II reactions being involved in the photobleaching of mTHPC (74) and identified mTHPP as the primary photoproduct (75). Similar results were obtained using the HPLC separation of mTHPC photoproducts after irradiation with 514 nm laser light in combination with MALDI-TOF MS and UV/Vis spectroscopy. Again, the formation of mono, di and trihydroxylated derivatives of mTHPC and an unidentified degradation product was reported (76). Interestingly, pulse laser irradiation of mTHPP at 647.5 nm resulted in the formation of benzoquinoid porphyrins followed by formation of dimeric (6) and oligomeric photoproducts (77).

ESR experiments of organic solutions of mTHPC were performed to elucidate the mechanism of photobleaching in more detail (78,79). mTHPC produces superoxide anion radicals more efficiently than Photofrin and while both singlet oxygen and superoxide anion radicals contribute to the photobleaching the latter is primarily involved in the conversion to mTHPP. Initial in vitro photobleaching experiments were undertaken with Chinese hamster lung fibroblasts and showed that the rate of photobleaching was much higher for mTHPC than mTHPP or Photofrin (80). A study of mTHPC in solution with fetal calf serum (81) showed that this process depends on oxygen level and alterations in the microenvironment of the sensitizer. A clear relationship between 1O2 and bleaching rate was found (82) and the singlet oxygen concentration is inversely related to cell survival (83). Likewise, there is a correlation between drug concentration and rate of photobleaching for a fixed laser fluence rate (84).

Overall, the light-induced chemical changes of mTHPC described in the various works covering ex vivo experiments are similar in terms of identified photoproducts. However, the quantitative findings differ strongly depending on the experimental conditions and the microenvironment (83,85–89). This limits the utility of the in vivo photobleaching models. For example, the intracellular photobleaching in a murine macrophage cell line was found to exhibit a complex dependence on oxygen level and an inverse dependence on fluence rate (90). For rat skin the photobleaching kinetics were biphasic and were different from those for tissue oxygen consumption (91). Monitoring photobleaching in vivo is especially difficult in an interstitial environment (55).

Few studies have investigated the relative photostability of various PS. For example, a study investigating the stability of hypericin in various model systems noted significant differences in stability, with mTHPC being one of the least stable PS compared to phthalocyanine derivatives and hypericin (92). Likewise, a recent study compared Photoditazine, Radachlorin and Foscan and found Foscan to be the most stable of the three PS (93). This can be attributed to the higher degree of aggregation for mTHPC in solution, which inhibits singlet oxygen formation.

Pharmacology and biochemistry

Uptake, localization and metabolism

Uptake.  The uptake of the compound into cells appears to be pH independent (94). A comparative study of the uptake of some PS into human breast cancer cells showed a pH-dependent uptake for Hp IX and similar results were obtained with other human cancer cell lines (95). However, in contrast to this, its activity once taken up decreased with extracellular pH (better at 6.8 than 7.4). Likewise, low temperature (4°C versus 37°C) resulted in increased photosensitivity of human colon carcinoma cells (95,96). The uptake is determined to some extent by the deaggregation process of the drug and the drug appears to bind to lipoproteins (97). This was further indicated by experiments with [14C]-mTHPC which was shown to bind to several lipoprotein fractions of the human serum. The approximate distribution was: VLDL 6%, LDL 22%, Lp(a) 17%, HDL 39% and soluble fraction of mTHPC 16% (98). The exact physicochemical type of binding to these species is still unknown. However, a binding study of 5,10,15,20-tetra(4-hydroxyphenyl)porphyrin with human serum albumin showed that hydrophobic interactions appear to be the main driving force (99). Interestingly, this study indicated that chromophore binding reduces the α-helix structure of the protein.

The uptake of Foscan is affected by many factors. For example, in vitro studies indicated that the PDT activity is five times lower in the presence of protein as compared to serum-free medium (100). It appears that the drug is taken up in aggregated form and that subsequent monomerization is a slow process which may explain the observed time delay in maximum PDT activity. However, the presence of serum during the illumination period had no effect indicating that the drug may be sequestered upon entering the cell (101). There is also evidence for the existence of aggregated forms of Foscan in the presence of protein which are not protein bound, indicating the possibility for similar states of matter in vivo (102). Aggregation effects were also noted in HeLa cells (103). A model study investigated the release and redistribution of Foscan from various plasma proteins. The rate of redistribution was low and HDL-mediated endocytosis was proposed as the main mode of drug transport in cells (104). Nevertheless, the uptake of LDL and thereby mTHPC is far more efficient and may reflect the real uptake pathway for the drug. Administration of glucose resulted in increased PDT effect in animal models, most likely due to changes in tumor physiology or transport processes (96). Metabolic inhibitors were reported to have no effect (105). In a mouse model the plasma mTHPC level correlated with the PDT effect, while the tumor uptake did not, indicating that shorter drug-light intervals with low drug doses might be better for treatment (106).

A detailed study compared the pharmacokinetics in mice and humans and found that the drug distribution over the lipoproteins and the metabolism of the lipoproteins had no impact on the plasma pharmacokinetics. Thus, the longer time needed for high drug concentrations in human plasma compared to that in mice could indicate the formation of a drug depot. The different pharmacokinetics between rodents and human illustrate the problems associated with using animal models for predicting drug behavior in humans (107).

Localization.  The exact localization of the PS in the cell determines its impact on the molecular machinery and thus the efficacy of the PDT effect. This is mainly a result of the short life time and diffusion constant of the reactive oxygen species. In practical terms the identification of the localization sites has become much easier since the advent of confocal laser scanning microscopy. Administration of the drugs with organelle specific probes which have fluorescence maxima different from the PS now allows the identification of the intracellular sites where PS accumulate and the damaged sites after photoactivation.

Generally speaking the localization of PS depends on their charge, their hydrophobic or hydrophilic properties, their aggregation state and the molecular substituent pattern. As a rough approximation hydrophobic PS with ≤2 negative charges pass the plasma membrane easily and typically show good uptake. More polar PS with >2 negative charges cannot pass the membrane via diffusion and are taken up by endocytosis. Thus, the various PS exhibit quite different intracellular localizations (26). This can be modulated significantly through use of different delivery vehicles and strategies for the PS drugs (108).

In terms of organelles the most interesting ones for PDT are the lysosomes, mitochondria, plasma membrane, Golgi apparatus and endoplasmatic reticulum. Examples for PS localizing (predominantly) in these organelles include aluminum phthalocyanine disulfonate, benzoporphyrin derivative (BpD), deuteroporphyrin IX and Foscan. However, it must be taken into account that intracellular redistribution and relocalization may occur as a result of light-induced relocalization (109). Even more specific intraorganellar localizations have been observed for PS related to the natural protoporphyrin IX system. For example, dicationic protoporphyrin IX PS were found to be highly effective inhibitors of the peripheral benzodiazepine receptor in the outer mitochondrial membrane, which is upregulated in some tumors (110). The binding to such specific receptor sites is the driving force for the development of third-generation targeted PS bioconjugates. For an excellent review on the various physicochemical parameters affecting PS localization see Mojzisova et al. (111).

The subcellular localization of mTHPC in human adenocarcinoma cells was studied by Melnikova et al. using fluorescence microscopy (112). Initial studies reported that mTHPC localized generally within cellular organelles, but not the nucleus. After cell illumination, photosensitized damage was detected using a fluorescent probe. The mitochondria and the Golgi apparatus were found to exhibit extensive cytoplasm vacuolization and other alterations. Kessel initially described the localization in mitochondria, where illumination resulted in a release of cytochrome c (97). Chinese hamster lung fibroblasts exhibited a diffuse localization in the cytoplasm (113), as did murine macrophages (114). A 2005 study of mouse sarcoma cells using fluorescence anisotropy imaging showed localization of Foscan in the nuclear envelope (115). No such localization was found for other PS (PPIX, LS11, Photofrin, Pc4, HPPH). Some studies reported localization of mTHPC in the lysosomes (116). More details are given in Table 1 for individual cell lines.

Table 1.   Cell lines used for in vitro studies with mTHPC in solution.
Cell lineStudyCommentsYear  Ref.
Crayfish mechanoreceptor neurons from Astacus leptodactilusEffect on neuronsIrreversible loss of neuron activity at nm concentrations2004237
Drosophila melanogasterSomatic genotoxicityNo effect1997196
Epithelial cell lineTwo-photon absorption PDTPossible with mTHPC2007546
Hamster, baby; kidney cells BHK-21Test of cell viability assaysDoxorubicin increases treatment effect2004460
Hamster, Chinese; lung fibroblasts V79PhotobleachingComparison with mTHPPand Photofrin1994  80
Hamster, Chinese; lung fibroblasts V79PDT, comparison with mTHPP and PhotofrinmTHPC > mTHPP > Photofrin1994113
Hamster, Chinese; lung fibroblasts V79Phototoxicity and comparison with mTHPC-MD2000mTHPC-MD2000 has 100 times less dark toxicity and is 10 times less cytotoxic1997  223
Human bile duct cancer, BDCComparison Foscan and FoslipHigh potency for both, easier application with Foslip2007  232
Human bile duct cancer, various cell linesEffect of cell phenotype on mTHPC PDTSignificant variation between individual cell lines2010  238
Human breast carcinoma MCF-7Combined use of PDT and radiotherapyEffect of both treatments is additive1995  234
Human breast carcinoma MCF-7Cytotoxicity using ATP cell viability assayLD50 4.55 μg mL−1, λ = 650 nm, 2.5 J cm−21995  217
Human breast carcinoma MCF-7Phototoxicity and comparison with mTHPC-MD2000mTHPC-MD2000 has 100 times less dark toxicity and is 10 times less cytotoxic1997  233
Human breast carcinoma MCF-7ResistanceNo induced resistance to chemo or radiotherapy or subsequent PDT1998  200
Human breast carcinoma MCF-7Fractionated light treatmentFractionated light gives higher phototoxicity1998  153
Human breast carcinoma MCF-7Fractionated light treatmentIrradiation with on/off light gives doubling of cytotoxicity2000  154
Human breast carcinoma MCF-7/DXREffect on multidrug resistant cellsGood effect, more cell killing at same dose in drug resistant strain2001229,230
Human breast carcinoma MCF-7DNA mismatch repairRepeated PDT does not result in loss of DNA mismatch repair2002  201
Human breast carcinoma MCF-7Localization and primary effectER and Golgi2003
2003
  117
  118
Human breast carcinoma MCF-7Effect of 5-fluoro-2′-deoxyuridine 2003  459
Human breast carcinoma MCF-7Effect of aggregation statesProgressive sensitizer aggregation with increasing incubation time2007  221
Human breast carcinoma MCF-7Subcellular localizationLocalized in ER and Golgi after 3 h. After 24 h mainly damage to ER; activation of the caspase-7 apoptotic pathway2007  190
Human breast carcinoma T47DEffect of pH on uptakeNo effect2003
2005
  95
  565
Human colon adenocarcinoma Colo 201PDTLD50 0.45 μg mL−1, 20 h, λ = quartz lamp, 3 J cm−2, localization in lysosomes2002  116
Human colon adenocarcinoma CX1Test of hematogenous disseminationMinimal tumor cell survival in blood, SF = 0.02%1998  226
Human colon adenocarcinoma HT29PDT and comparison with HpDmTHPC: LD50 0.2 μg mL−1, 1 day, λ = 650 nm, 10 J cm−2; HpD: LD50 4.2 μg mL−11996  222
Human colon adenocarcinoma HT29UptakeUptake depends on presence of proteins in serum1998  100
Human colon adenocarcinoma HT29PhotobleachingRole of aggregation1998  88
Human colon adenocarcinoma HT29Localization studyDiffuse localization outside the nucleus1999  112
Human colon adenocarcinoma HT29Effect of α-tocopherolNo photoprotection from α-tocopherol, at concentration >0.33 mm enhanced PDT effect1999168,158
Human colon adenocarcinoma HT29Effect of NaN3Strong inhibition of PDT1999  158
Human colon adenocarcinoma HT29Effect of fluence rateCorrelation between fluence rate, oxygen depletion and PDT effect2002  157
Human colon adenocarcinoma HT29Apoptosis effectsCyt c release and 12-fold increase of caspase-3 activity within 24 h2004  165
Human colon adenocarcinoma HT29Cell deathMainly necrosis2005  167
Human colon adenocarcinoma HT29ApoptosisEffect on apoptosis as measured by polyclonal antibodies to active caspase-3, active caspase-7, c-PARP
Comparision with KB monolayer cells and HT29 spheroids and HT29 xenografts
2009185
Human colon adenocarcinoma WiDrEffect of pH on uptakeNo effect1999 94
Human colon adenocarcinoma WiDrEffect of pH on uptakeNo effect2005565
Human epidermoid carcinoma A431Comparison of various PSFoscan lowest LD50, Photofrin lowest IC502010539
Human fibroblasts BCT-27PDT 2004199
Human gynecological tumorsPDT of ex vivo cellsIndividual treatment conditions required1999233
Human keratinocytesPhotobleaching 2004 86
Human keratinocytesPhotobleachingMore rapid at fixed laser fluencerate at higher drug concentration2005 84
Human malignant glioma U87MGEffect of pH on uptakeNo effect2005565
Human mesothelioma H-meso-1PDT 2004199
Human mesothelioma H-meso-1Effect of the TAT-RasGAP317–326 peptideSignificantly higher apoptosis rate in the presence of TAT-RasGAP317–326 at 0.04 μg mL−1mTHPC but not at 1.0 μg mL−1mTHPC2007191
Human microvascular endothelial cells hMVECPDT 2004199
Human myeloid leukemia K562DNA damage and repairNo DNA damage1997197
Human oral SCC H376, VB, UPInvasion promoting tumor factorsActivity of MMP-2, MMP-9, MMP-13, uPA and VEGF downregulated in some cell lines2006253
Human ovarian cancer SK-OV3Comparison with taxol and cisplatinEffect on cell proliferation: mTHPC: IC50 0.9 μμ, 1 day, λ = 650 nm, 15 J cm−2; cisplatin: IC50 4.6 μμ; taxol: IC50 78 nm2000224
Human prostate cancer LNCaPFoscan versus FospegNo dark toxicity with Foscan or Fospeg
Fospeg more effective:
Fospeg: LD50 0.15 μg mL−1, λ = 652 nm, 180 mJ cm−2
Foscan: LD50 1.2 μg mL−1, λ = 652 nm, 180 mJ cm−2
2009484
Human prostate carcinoma LNCaPEffect of 5-fluoro-2′-deoxyuridine 2003459
Human red blood cellsHemolysisPhthalocyanine PS > mTHPC1998228
Human SCC A-431Effect on mitochondria 2009176
Human SCC CNE2 nasopharyngeal carcinomaPDT and comparison with MC540 2000225
Human SCC CNE2 nasopharyngeal carcinomaPDT and comparison with BpDBetter uptake of mTHPC and more mitochondrial damage2000166
Human SCC HNXOEPDT 2004199
Human SCC NPC/HK1 nasopharyngeal carcinomaPDT and comparison with MC540 2000225
Human SCC NPC/HK1 nasopharyngeal carcinomaPDT and comparison with BpDBetter uptake of mTHPC and more mitochondrial damage2000166
Human SCC NPC/HK1 nasopharyngeal carcinomaApoptosisCells apoptotic after 1 h, significant decline in Bcl-2 expression2008227
Human skin fibroblastsEffect of pretreatment 1997145
Human skin fibroblastsEffect of pH on uptakeNo effect2005565
Human skin fibroblasts GM00316BEffect of the TAT-RasGAP317-326 peptideNone2007191
Monocyte cell line U937 differentiated into macrophagesPDT activation of macrophage-like cellsActivation occurs1999213
Mouse colon carcinoma Colo26Test of diode system as light sourceGood effect1996550
Mouse colon carcinoma Colo26Photobleaching: Effect of fluence rateLower fluence rates increase efficacy2001218
Mouse embryonic fibroblastRole of apoptosis-related genesP53 and ATM play no role in PDT necrosis, but might be required for apoptosis2003184
Mouse friend erythroleukemic cells DP16PhotobleachingPhotobleaching as a measure of PDT damage in vitro2002 85
Mouse mammary sarcoma cells EMT6Localization study using fluorescence anisotropyLocalized in the nuclear envelope2005115
Murine fibrosacrcoma L929Effect of antiapototicsNo effect2001188
Murine fibrosacrcoma RIF-1UptakeStrong retention of mTHPC compared to other PS1999101
Murine fibrosacrcoma RIF-1Localization/comparison with phthalocyanine PSDiffuse localization1999538
Murine fibrosacrcoma RIF-1Effect of trypsinizationDepends on type of PS and fluence rate2001172
Murine fibrosacrcoma RIF-1, PDT resistant mutant strainsRadiation induced PDT resistant strainsNo cross-resistance2001235
Murine fibrosarcoma FsaREffect of poly(adenosine diphosphate-ribose) polymeraseEnzyme is induced by PDT2003170
Murine glioblastoma cells C6Study of DNA repair after PDTNo significant effect on DNA repair within treatment regime2000198
Murine hepatoma cells MH22Post-treatment conditions 1997180
Murine hepatoma cells MH22Energy metabolismMore necrosis under low glucose conditions2003181
Murine hepatoma cells MH22Test of cell viability assaysDoxorubicin increases treatment effect2004505
Murine hepatoma cells MH22Effect of doxorubicinMore effective in combination with PDT than either alone2006461
Murine leukemic cells L1210PDTLD50 0.88 μg mL−1, λ = 514 nm, 25 J cm−2
LD50 6 μg mL−1 in darkness
1994216
Murine leukemic cells L1210Uptake of PEG/EtOH formulationSlow uptake, localization in cytosol; irradiation gave mitochondrial > lysosomal ≫ membrane photodamage, and a rapid apoptotic response1999566
Murine leukemic cells L1210Mode of actionInactivates the antiapototic protein bcl-22001189
Murine leukemic cells P388Test of formulations and localization 199997
Murine Lewis lung carcinoma, LLC1PDTLD50 with 60 mJ cm−2 and 400 ng mL−12010268
Murine macrophage J774A.1Time-resolved imagingDiffuse extranuclear localization2001114
Murine macrophage J774A.1PhotobleachingInverse dose-rate correlation, complex dependence on deoxygenation2002 90
Murine melanoma B16A45ApoptosisRate of apoptosis varies with PS and cell type, mTHPC is a better apoptosis inducer than ALA2002182
Apoptosis inhibitors modify PDT only slightly2002183
Murine myeloid leukemia cells M1Comparison with merocyanine 540mTHPC much more potent and selective1998186
Murine myeloid leukemia cells M1Study of aggregation statemTHPC localized at the mitochondria and perinuclear region2000164
Murine myeloid leukemia cells WHI 3B (JCS)Comparison with merocyanine 540mTHPC much more potent and selective1998186
Murine myeloid leukemia cells WHI 3B (JCS)Study of aggregation statemTHPC localized at the mitochondria and perinuclear region, pronounce release of cytochrome c2000164
Murine neuronsEffect on neuronsStability of neurons toward PDT in comparison to satellite glia and MCF-7 cells. MCF-7 significantly more sensitive2009236
Murine skin fibroblasts 3T6Heat-shock protein expressionNo effect of mTHPC PDT1997173
Rat colon adenocarcinoma PRObApoptosisRate of apoptosis varies with PS and cell type2002182
Rat pheochromocytoma PC 12 cellsUptake 1997283
Rat prostate adenocarcinoma MAT-LyLuDosimetry 2005 83
Staphylococcus aureusTest of antibacterial toxicityAntibacterial toxicity in the dark1999411
Streptococcus mutans and Streptococcus sobrinusmTHPC and hypericin for dental caries study with cariogentic bacteriaStreptococcus sobrinus:
m
THPC: LD100 5 μg mL−1, λ = 400–505 nm
Hypericin: LD100 2.5 μg mL−1, λ = 400–505 nm
Streptococcus mutans: mTHPC: Dark toxicity: 1.25–10 μg mL−1; CR required administration of both PS
2009552

A detailed confocal fluorescence microscopy study of a human adenocarcinoma by Guillemin and coworkers showed only weak localization in lysosomes and mitochondria. Instead, Foscan was found to be localized in the endoplasmic reticulum (ER) and the Golgi apparatus and the latter two were the sites of primary PDT damage (117,118). In this context it has been speculated that the human ATP-binding cassette transporter isoform B6 (ABCB6), which is located in the Golgi and has elevated expression levels in breast cancer patients, might play a role in transporting porphyrin-related compounds (119).

The tissue localization has been studied in many experiments most of which are discussed below in the animal model section. An interesting effect noted in an early study was the difference between mTHPP and mTHPC (120). Chemically, both are similar in hydrophobicity. Nevertheless, the porphyrin localized mainly in the stroma of tumors (breast cancer implanted in mice) while the chlorin was distributed in the vascular interstitium and neoplastic cells of the tumor. Thus, PDT with the former resulted mainly in destruction of the microvasculature of the tumor while the latter affected both the vascular walls and the tumor cells. However, the PDT drug blood serum levels and vascular photosensitization appear to be decoupled (69) indicating a more indirect effect of the PS on the blood capillaries.

The time course of the uptake differs from organ to organ. A squamous carcinoma cell (SCC) hamster model showed initial uptake in the liver and kidney and then later in the blood vessels and smooth muscle (121). However, many of these studies report overall tissue distribution or bulk uptake and that tells little about the real extravascular distribution. This was clearly shown in a study by Mitra et al. who used two-color confocal spectroscopy and a mouse mammary tumor model and identified the intratumor distribution of the drug. It clearly varies significantly with time and spatially within the tumor (122). All these aspects clearly have clinical implications.

Metabolism.  An important question in drug development is whether mTHPC is metabolized by the body. However, only a small number of studies have addressed this question. Analytical work on samples of plasma, bile, feces, urine and liver using HPLC and electrospray MS confirmed that mTHPC was not metabolized but excreted unchanged apart from fractions of mTHPP and hydroxylated mTHPC derivatives which were already known to be photochemical oxidation side products (123,124). Its plasma binding is quite distinct from other PS (125). A study with radiolabeled Temoporfin in colorectal cancer induced mice showed a rapid clearance from blood and the concentration in the tumor reached a maximum at 2 days. Nearly 40% of the drug was excreted in the feces during the first day, almost none was recovered from the urine. The elimination half-life was estimated to be 10–12 days for this system (126).

Pharmacokinetics.  The pharmacokinetics of any PS depend on a variety of factors. These range from aggregation–deaggregation equilibria in the blood, binding to serum components, binding to and penetration through the blood vessel wall, diffusion through the organ/tumor parenchyma, potential metabolization and finally excretion. In principle the quantification of PS in tissue and blood is easy due to their fluorescence. For Foscan, ex vivo fluorescence spectroscopy is a relatively fast and reliable method (121) and can be accompanied by in vivo spectrofluorimetry and chemical analysis after extractions (127). However, quantification methods based on this are problematic and depend on the extraction method used and the type of PS. One example for this is the use of SolvableTM as a tissue solubilizer (128).

Other methods include HPLC analysis of tissue sample or administration of radiolabeled compounds followed by scintillation measurements. Likewise, noninvasive measurements based on tissue fluorescence are possible. In reality a comparison of pharmacokinetic data from different sources and laboratories is difficult. This relates to the use of different standards, sample preparation and the incompatibility of some animal models. Based on the different uptake and localization mechanisms the overall pharmacokinetics vary significantly from PS to PS and half-lives range from a few minutes to days (28). A good comparison of the pharmacokinetics of the various PS available up to the mid nineties was given by Moore et al. (129). Similar to the situation for uptake, the exact pharmacokinetics depend on the species and tumor model used (28).

For Foscan, the following data are based on a number of Phase I studies (130–132). The pharmacokinetics of mTHPC in humans was evaluated thoroughly in 1996 in a clinical study with concentration measurements of plasma, cancer and normal tissue biopsies (130). After drug delivery blood was taken in periodic time intervals and biopsies were taken immediately prior to PDT from 25 patients who suffered from various cancers. The maximum concentration of mTHPC in blood was reached by 10–24 h which distinguishes Foscan® from other drugs when delivered directly into the blood cycle. Depending on the study a half-life of the drug of 30–45 h was established (130,131). Probably, it is initially accumulated in the liver followed by a slow release mechanism. The pharmacokinetics of mTHPC compared to ALA was reviewed previously (133). Early studies in a murine model indicated that Temoporfin concentrations in heart and skeletal muscle decline much slower than in blood (134).

Clearly the interaction of Temoporfin with plasma is of relevance. A study of the distribution in human plasma and in a rat model in vivo concluded that the drug quantitatively binds to plasma components (125). The site of binding appeared to be highly localized to a hitherto unidentified nonlipoprotein fraction of plasma. This behavior is unique compared to other PS and might be responsible for the specific pharmacokinetic behavior of mTHPC. The importance of a careful study of the pharmacokinetics was shown again in a recent study on “compartmental targeting” of Foscan. A mouse model showed clearly that a fractionated double injection protocol was superior to a single dose administration of the drug (135).

Dosimetry

Many efforts have been made to develop effective PDT dosimetry methods (136). The photobleaching mTHPC (see above) has been proposed as one method. However, while the photobleaching rate is oxygen dependent and the oxygen concentration correlates with the photobleaching rate, this dependency is related to the microenvironment. Thus, without knowledge about the tissue oxygenation photobleaching cannot be used for dosimetry (82). Photobleaching results can differ widely depending on the experimental conditions making clear conclusions about the utility of dosimetry difficult (83,85–87). An alternative dosimetric method might be the determination of the mTHPC plasma level, as indicated by a comparative study of the mucosa of the oral cavity, the esophagus and the bronchi of 27 patients using light-induced fluorescence spectroscopy (131). This is supported by a study which compared dogs, rabbits, rats and humans (137).

Other methods included low-power remittance fluorescence (138), optic fiber spectrofluorimetry, reactive oxygen species assays using dichlorofluorescein determination (139) and soft tissue models based on agar gel (140), among others. Overall, it has to be concluded that an approximation of the appropriate drug dose from preclinical results is problematic. The biodistribution of the drug varies from tissue to tissue and from species to species. To use body weight and/or amount of surface area as a means of extrapolation from species to species is unreliable, and even variations between individuals are often huge (133,137). This is clearly a significant problem. A better approach might be taking into account the plasma concentration of drug and/or good fluorescence measurement and clinical experience (131). A study by Wang et al. criticized the correlation/prediction of the PDT response based on singlet oxygen production metrics (141). However, the model employed is rather specific and it is yet unclear how general these results are.

Another problem is how to effectively measure and control the various parameters that affect PDT during interstitial application. While this area is well developed for radiotherapy, phototherapeutical applications still require further developments (142). This is a fundamental problem irrespective of the tumor treated. A first animal study that attempted to address the problem of monitoring both explicit (fluence rate) and implicit parameters (photobleaching, oxygenation and blood volume) was performed recently and showed that indeed such a monitoring is possible, albeit difficult (55). PDT dosimetry is probably the most complex and difficult aspect of any PDT application. The exact methods used will always depend on the individual situation.

Formulation

Formulation is an important aspect of any drug development. For PS this is especially important as different treatment modalities (e.g. skin versus internal cancers) or chemically very distinct drugs (e.g. ALA versus porphyrin based drugs) require diverse application systems. Thus, significant potential still exists for the investigation of different formulations and drug delivery strategies for PS (143). For example, a possibility is the incorporation of the drugs into gel systems. The cubic phase (monoolein/water, 70:30, wt/wt) appears to be a suitable system as initial studies showed good stability of various PS in the gel formulations (144).

Due to the poor solubility mTHPC can only be used with a formulation process prior to administration. Initial applications used formulations in PEG and ethanol or propylene glycol (97). Some results point toward problems with regard to optimum administration of the drug. For human skin fibroblasts it was found that preincubation of mTHPC at 37°C for a day prior to administration significantly improved the PDT effect (145). This indicates problems with solubility (or drug preparation) of the active PS. Considerable effort has been spent on the preparation of nanocarrier formulations for PS (146,147). For mTHPC this is evidenced by the shift in developmental attention from Foscan® (a solution) to Foslip® (a liposomal formulation).

Light

As a photochemical reaction PDT requires investigations into the dependency on exciting wavelength, light intensity, fluence rate and type of light application, photophysical characteristics of the PS and so on. It is also dependent on the clinical setting, i.e. the type of cancer to be treated. Nevertheless, some general considerations, for example those made for photobleaching above, can be made for Foscan.

Early studies with malignant mesothelioma cells indicated that the drug-light interval has a significant effect on the therapeutic action. Typically selectivity is improved with longer drug-light intervals and Foscan showed better results with longer intervals than used for Photofrin (148). Higher light doses were found to be more advantageous than increasing the drug dose (149). Obviously, this also means that the light dose is important when considering the toxicity of the treatment for healthy tissue (150). The optimum drug-light interval varies with the tissue. Various studies addressed the effects of green (514 nm) versus red light (652 nm). Roughly speaking the tissue absorption is 2–3 times greater at 514 nm and 4–5 times as much light might be required to achieve the same phototoxic effect as 652 nm light (151). Even more importantly light penetration is shorter at 514 nm which reduces the chance of tissue perforations, e.g. in the esophagus.

Fractionation of light can also improve the PDT effect. However, the effects are very dependent on the dark intervals between light administrations. Typically, short dark times appear to be better. For example, an animal study on Rifi tumors indicated dark times of 30 s to be best (152). An interesting study using MCF-7, an estrogen-dependent human breast carcinoma cell line, showed that fractionated light, i.e. giving the illumination in short pulses (0.05 s light, 0.05 s dark) instead of continuous illumination for a few minutes increased the photodynamic effect significantly (ca 50% for mTHPC, somewhat less for mTHPC-MD2000) (153). A later study with on/off illumination delivering the same total light fluence, i.e. a 50% reduction of the power density, doubled the cytotoxicity (154). A study using an SCC model showed a clear dependence of the photodynamic effect on the fluence rate. Lower fluence rates at both 514 and 652 nm induced higher tissue damage but less selectivity (155). Other animal studies gave similar results (156). A detailed study by Coutier et al. correlated the fluence rate, tumor oxygenation and PDT effect and found that lower fluence rates limit the extent of oxygen depletion in the tumor and thus result in better PDT outcomes (157).

Mechanism of action

From a chemical viewpoint the mode of action of any porphyrin PS is based on simple photochemistry and mTHPC primarily acts through the generation of singlet oxygen like other PS. Early studies on the photodynamic effect in the presence of singlet oxygen scavengers showed a reduction in the photoinactivating ability of mTHPC (113). For example, sodium azide strongly suppressed PDT activity in human tumor cells, while superoxide anion radical, H2O2 or hydroxyl radical scavengers had no effect (158). However, optimization of current and future drugs requires a more detailed understanding of the intracellular chemical and biochemical reactions in molecular medicine terms. In conceptual cell biological terms this requires knowledge about the impact of PDT on cell signaling and cell metabolism (159). In clinical terms it is necessary to know the mechanism of tumor destruction at the individual tumor cell level, to understand vascular effects and unravel the related immune system effects (160). Unfortunately, single cell studies on the singlet oxygen distribution are thus far available only for other PS (161).

Cell signaling and metabolism.  PS can affect many different signaling pathways (162). For example, a number of PS induce a rise in intracellular Ca2+ and affect directly or indirectly Ca2+-binding chaperones, antiapoptotic proteins, caspases, phospholipases and the nuclear factor of activated T cells. The phospholipases link the calcium signaling to the lipid metabolism, e.g. through the release of acrachidonic acid derivatives. Likewise, cyclooxygenase-2 expression can be activated through PDT. Other affected second messengers are ceramide, cytokines and tryrosine kinases, especially mitogen-activated protein kinase and epidermal growth factor. PDT also acts on transcription factors, e.g. activator protein 1, NFκB and transcription factor E2F. Cell–cell interactions, e.g. cell adhesion can be influenced as well. Other regulatory factors such as cytokines and neutrophils or stress response proteins are important for the PDT effect as well. Other possible PDT effects include angiogenesis and tumor responses to changes in the oxygen level. The latter notably includes tumor hypoxia as PDT can rapidly deplete the tissue oxygen and affects the tumor blood supply. Note, that many of these responses are interconnected. For a detailed discussion of the effect of the various PS see Castano et al. (27). Likewise, NO might be an important target for PDT action. While data on the interplay of mTHPC and NO action are sparse, the importance of nitric oxide has been discussed widely for other PS (163).

For Foscan the available data are as follows. A study by Kessel in 1999 showed that illumination of murine leukemia cells treated with mTHPC resulted in the release of cytochrome c and activation of caspase-3 resulting in an apoptotic response (97). Mitochondrial damage and cyt c release was also described for other myeloid leukemia cells (164), human colon adenocarcinoma cells (165) and squamous cell carcinomas (166). Later Bezdetnaya and coworkers showed that the ER and Golgi are the sites of the primary effects (117,118). They clearly showed that enzymes in the Golgi, such as uridine 5′-diphosphate galactosyl transferase, or in the ER, such as NADH cyt c reductase, are inactivated through PDT treatment, while mitochondrial marker enzymes (cyt c oxidase and dehydrogenases) were unaffected (167). In order to correlate these data it must be noted that 24 h post-treatment the fluence dependency of the PDT effect was similar for changes in mitochondria and cell death (118). Thus, although mitochondria are not affected directly they will be affected significantly by late and indirect effects. This gives rise to a model wherein the ER/Golgi complex originates a death signal for the mitochondrial apoptotic processes. Thus, ER/Golgi localizing PS act in a different, more indirect manner compared to mitochondria localizing PS.

Reactions of the lipid peroxidation pathway appear to be not very important for the Foscan action. A study of human adenocarcinoma cells which incorporated α-tocopherol, a lipophilic phenolic antioxidant, did not elicit any photoprotection against PDT. Instead, the mTHPC PDT effect was enhanced at concentrations of 0.33 mm and above (158,168). An interesting study investigated the effect of radio- and phototreatment on the level of serum α-N-acetylgalactosaminidase, an extracellular matrix degrading enzyme that appears to be exclusive for cancer cells (169). While radiodynamic treatment reduced the level of this enzyme significantly, PDT lowered it to background level within 2–3 days after PDT. The level of this enzyme appears to be a suitable diagnostic tool for dosimetric applications. Another notable enzyme activation involves poly(adenosine diphosphate-ribose) polymerase, a key regulator of cell death-survival transcriptional programs. It is activated significantly by Photofrin or Foscan PDT (170). This induction occurred 30 min after PDT, followed by further increases in enzyme levels by 2 h.

Few biochemical studies of isolated cell organelles were performed to assess the intracellular Foscan PDT effects. Both Type I and II effects were noted in isolated rat mitochondria. The PDT treated mitochondria had a reduced membrane potential and impaired Ca2+ uptake (171). Similarly, only limited information is available for the impact of Foscan PDT on cell adhesion. Post-PDT cell removal by trypsinization was found to depend on the PS type and the fluence rate (172).

Sometimes laser hypothermia is compared with PDT as both use the same application principles. However, their modes of action are different, especially with regard to collagen damage. A comparative study clearly showed no effect of mTHPC PDT on collagen-related heat-shock protein expression (173). Likewise HpD PDT had no effect; only riboflavin PDT gave an upregulation of the HSP47 heat-shock protein (174). This supports the notion that PDT “spares” the connective tissue. In this context Mitra et al. developed an interesting model system that utilized green fluorescent protein (GFP) as an analytical tool of the PDT effect. They transfected EMT6 cells with a plasmid containing the gene for GFP driven by an hsp70 promoter (175). mTHPC induced a concentration dependent GFP expression in cells and in a rat model.

Cell death.  Ultimately the aim of PDT is the death of unwanted cells and tissues in the body. The type and degree of cell mortality depends on the various factors involved in PDT and typically two types of cell death are considered. Necrosis is a rapid form of cell death, whereby the cell organelles are destroyed and the plasma membrane ruptures. This results in inflammation and a release of the intracellular materials. In contrast, apoptosis is characterized by a shrinking of the cell and blebbing of the plasma membrane. The cell organelle and plasma membrane structure are maintained for a considerable time. Ultimately apoptosis results in vitro in fragmentation into vesicles while in the body the cell remnants are taken up by phagocytes without inflammation. Apoptosis is a highly controlled process and involves the transcriptional activation of specific genes, DNA degradation and caspase activation. By now, other forms of cell death, e.g. programmed necrosis, mitotic cell death, autophagy and lysosomal death pathways have been described. In most cases PDT related studies focus on the first two types. However, Foscan has been implicated in autophagy as well (176). Necrosis and apoptosis can often be induced at the same time and the exact mode of cell death then depends on the PS, cell type, oxygen supply and experimental conditions. For basic reviews on cell death in PDT see the following articles: (162,177,178). While evidence for the signaling role of reactive oxygen species is mounting (179) it remains an open question to what extent the various effects are directly related to PDT or if they are more general effects resulting from cell damage.

Both necrosis and apoptosis effects are associated with the action of Temoporfin. One indication is that low levels of post-treatment energy metabolism favor further cell decay (180). A lack of glucose in the incubating medium significantly increased the extent of necrosis (181). Bourréet al. undertook a first in vitro study to quantify the apoptotic effect of Foscan. ALA (proto IX) and, more so mTHPC, were found to be strong apoptotic inducers. The maximal apoptosis enrichment factor, a measure of this effect, depended on the PS and cell type (182). Interestingly, apoptosis inhibitors had only slight effects on the PDT efficacy indicating that necrosis and apoptosis might be linked and share common initiation pathways. This requires active caspases and these results would indicate that apoptosis inhibition reorients cells to necrosis (183). A related study investigated the role of two genes, p53 a tumor suppressor gene important for cellular stress response and ATM, a gene mutated in patients suffering from ataxia telangiectasia. mTHPC PDT did kill the cells with these mutations quite efficiently through necrosis. Apoptosis appeared to be more a long-term process that depends to some extent on the p53 and ATM function (184). A detailed assessment of the expression of caspase-3, caspase-7 and cleaved poly-ADPribose polymerase 1 in Foscan treated cells has been given by Bressenot et al. (185).

mTHPC resulted in a much better apoptotic effect than merocyanine 540 in murine myeloid leukemia cells and cleaved the DNA to very small 150 base pair fragments (186). Induced apoptosis was observed in an intracranial tumor model (187) and in human colon adenocarcinomas (116). The action of some cationic PS can be counteracted to some extent through antiapoptotic protocols. A study of mouse fibrosarcoid L929 cells with an overexpressed protooncogene (bcl-2), which protects cells against apotogenic stress, showed no evidence for a positive or negative effect on the PDT results (188). However, for murine leukemia cells it was clearly shown that the first detectable effect of several PS, including mTHPC, is the loss of activity of the antiapoptotic protein Bcl-2, followed by cyt c release and caspase-3 activation (189). A detailed study using MCF-7 cells addressed the question whether the post PDT apoptotic effects originated from the ER/Golgi or the mitochondria. The study clearly showed localization of Foscan in the ER and Golgi. After 3 h leakage from the Golgi was observed and prolonged incubation times showed photodamage to Bcl-2 in the cell extract, but not in the mitochondrial fraction. Likewise caspase-7 and -6 activation was observed indicating that localization in the ER enhances the photoactivation of the caspase-7 apoptotic pathway (190).

An intriguing treatment possibility is the coadministration of apoptosis inducing drugs. One such possibility to increase the tumor selectivity is the presence of the TAT-RasGAP317–326 peptide which sensitizes tumor cells to cytostatic agents. A comparison of H-meso-1 and human fibroblast cell cultures showed that, indeed, the PDT effect is enhanced by peptide administration but only in the H-meso-1 cells. This effect occurs only at low Temoporfin concentrations (0.04 μg mL−1). No such effect was found with 0.10 μg mL−1 Foscan (191). Thus, this effect is dose dependent. Another important effect in tissues is the bystander effect, i.e. the degree to which a dead cell results in death of a neighbor (192). A model study using MDCK II cells indicated that this bystander effect was significantly lower for mTHPP than for Photofrin or ALA PDT and treatment with metabolic inhibitors (193).

Any phototreatment has the potential to affect DNA at the molecular level through photochemical reactions. This occurs either through direct absorption by nucleobases or through photosensitized reactions involving endogenous PS (natural porphyrins and flavins) or the drug themselves. DNA is highly susceptible to singlet oxygen, resulting in single strand breaks and free radicals. ALA and porphyrin based PDT clearly can result in DNA damage (194). However, while this probably does not give lethal effects the mutagenic potential depends on the cell type and the effectivity of the repair mechanisms (195). No evidence was found for Temoporfin genotoxicity using a simple Drosophila melanogaster model (196). Likewise no DNA damage was found in in vitro tests with human leukemia cells (197). This study revealed DNA damage upon PDT with HpD or methylene blue, indicating quite different effects of various PS. Use of murine glioblastoma cells showed that mTHPC PDT does induce DNA damage in a dose-dependent manner but that treated cells are able to repair this damage (198).

A different issue is the relative susceptibility of different tissues and cell types to PDT. A comparative study of microvascular endothelial cells, fibroblasts and tumor cells indicated that endothelial cells are not per se more sensitive than other cell types (199). Only continued drug uptake after 24 h resulted in increased photosensitivity under certain conditions. PDT also does not induce any resistance to chemo or radiotherapy or subsequent cycles of PDT in human breast cancer cells (200). DNA mismatch repair-deficient cells are known to be resistant to many chemotherapeutic drugs and to radiotherapy, and have the potential of rapidly acquiring additional mutations leading to tumor progression. Using in vitro cell lines either proficient or deficient in DNA mismatch repair no differences were found between the cell lines upon Foscan PDT. Thus, PDT appears to not induce loss of DNA mismatch repair nor does loss of mismatch repair result in resistance to PDT (201). But how do all these mechanisms lead to tumor destruction? Tumor eradication requires and relies not only on effects at the molecular level, i.e. individual cell death, but even more so involves more “indirect” effects such as vascular and immune system effects.

Direct tumor cell effects.  This might be considered the first target of PDT. However, studies with several PS (mostly with Photofrin) showed that while PDT results in a decrease in the number of tumor cells, the overall effect is not enough for tumor eradication. This is a result of the often inhomogenous PS distribution, of photobleaching and the requirement for oxygen, which limits the utility of PDT in hypoxic tissue. The latter may be overcome by using lower light fluence rates or fractionated light delivery.

Vascular effects.  Almost from the advent of PDT studies it was clear that vascular effects impact long-term tumor control. In general these effects are associated with vascular damage that occurs after the PDT treatment and result in tumor hypoxia. Depending on the PS various mechanisms are involved. These include vessel constriction and vascular leakage, mostly related to platelet activation and aggregation. Early studies with chlorins noted that the primary target of PDT is often the tumor vasculature (202,203). Although differences exist in the exact distribution of Hp and mTHPC the latter seems to act in a more indirect manner on the blood capillaries (69). Animal models showed that the exact nature of the PDT effect depends on the pharmacokinetics. Thus, often an “early” response can be differentiated from a later effect in tissue (204). While tumor and plasma drug levels often do not correlate with PDT efficacy the Foscan concentration in leukocytes does. This indicates that leukocytes might play a role in the vascular damage process (205). For example, a detailed study of the pharmacokinetics of human tumor xenografts in mice showed that plasma levels of mTHPC decrease exponentially with time while the tumor drug levels remained at maximum for 48 h. At 3 h postadministration the drug was located in the blood vessels and only later distributed in the rest of the tumor. Illumination at 3 h resulted in a 100% cure rate while illumination at 48 h resulted in tumor regrowth and only 10% cure. Thus, the early vascular response appears to be responsible for optimum Foscan PDT response (206).

Immune system effects.  The immune system plays a significant role in the success of any PDT treatment. Based on initial studies with Photofrin it is now accepted that PDT can result in the generation of antitumor inflammatory cells and can lead to a persistent antitumor immune response. The advantage of this response is that it can be elicited by PDT even when not all cells are killed directly. There are even indications that Photofrin PDT can be used to generate antitumor vaccines (207). The immune system effect involves complex signaling pathways and relies on cytokines, growth factors and neutrophils all of which are significantly affected by PDT (160,208).

Secondary effects of the oxidative stress imposed by PS include vascular damage, ischemia-reperfusion injury, cytolytic activity of inflammatory cells and tumor-sensitized immune reactions (209). The latter was investigated through adjuvant administration of mycobacterium cell-wall extract, a nonspecific immunostimulant that gives a local inflammatory response associated with antitumor activity (210). Studies of a mammary sarcoma revealed that the PDT effect of various PS including mTHPC could be increased by a single treatment of this extract directly after light treatment. Mouse models clearly showed that Photofrin or Foscan PDT of solid tumors results in a strong and lasting induction of systemic neutrophils mediated by complement activation (211). More detailed studies revealed an increase in neutrophilic myeloperoxidase and an expression of MHC class II molecules in PDT-treated tumors. The most important regulatory inflammatory cytokine appears to be IL-1β, which inactivation diminished the PDT cure rate (212).

Similar to other PS mTHPC PDT activates macrophage-like cells (213). A detailed study of a model system revealed a light-energy dependent production of tumor necrosis factor TNF-α and a fluence dependent release of NO in U937ø cells. Foscan treatment of rat liver tumors showed that while PDT effectively necrosed the tumor tissue it had no effect on the growth of nonilluminated tumor areas in the same liver. PDT did not result in an increase of T cell numbers, natural killer (NK) cells or macrophages in nonilluminated tumors. Thus, no PDT-induced systemic immune response was observed in this system (214).

In vitro tests and animal models

In vitro tests

The photodynamic action of mTHPC became clear quickly after its synthesis, for example in a cost–benefit analysis comparing it with other PS (44,215). Naturally, the early tests included mostly in vitro tests of various cell lines. A survey of cell lines used for studies with Foscan, i.e. simple solutions of mTHPC, is given in Table 1, which also gives a brief description of the main results.

Initial tests with murine leukemic cells (216) or Chinese hamster lung fibroblasts (80,113) indicated that Temoporfin would be a better PS than Photofrin. This was substantiated by studies of human colorectal adenocarcinoma grafted subcutaneously in mice (216). Next were studies with human breast cancer cell cultures that indicated almost a total cell killing at nontoxic drug concentrations (217). Other studies indicated that lower light doses might be better (100) and experiments addressed the role of reactive oxygen scavengers (158), the beneficial effect of lower fluence rates (218), activation of phagocytic capacity (213) or the biodistribution of the drug with time (219,220), to name only a few. Initial studies on the effect of PDT on cell adhesion have also been reported (172). A study of the intracellular aggregation processes in MCF-7 cells indicated progressive sensitizer aggregation with increasing incubation time. Fluorescence lifetime imaging measurements showed a substantial decrease in the lifetime of mTHPC fluorescence at 24 h compared to 3 h. In addition, the intracellular localization changed from a diffuse pattern at short incubation times to a punctiform pattern at 24 h. Thus, the loss of photosensitizing efficiency at higher mTHPC concentrations is probably due to self-quenching of the triplet states of the PS (221).

mTHPC ticked more of the boxes of an optimum PS than other PS available in the early nineties. A comparison of its effect in human colon adenocarcinoma with that of BpD showed that it was more efficient by a factor of 20 (222). However, even the then available pegylated mTHPC derivatives (see below) appeared to be better suited than the unpegylated form (223). For an ovarian cancer cell line it was shown that the cytostatic cytotoxicity of mTHPC is comparable to that of cisplatin and only one order of magnitude below that of taxol (224). Similarly, Temoporfin was superior to merocyanin 540 (225) and HpD (166) in nasopharyngeal cells. In vitro studies also indicated the utility of PDT to perhaps suppress hematogenous metastasis (229). Cell studies indicated a rapid onset of apoptosis in such cells (227). Naturally, Foscan is not always the best PS for everything. Studies on the photoinduced hemolysis of red blood cells showed that cationic and hydrophobic phthalocyanines have improved activity compared to mTHPC and other PS (228).

Experiments with human breast cancer cells expressing a multidrug resistance phenotype showed that both the resistant and normal cancer cells showed a similar uptake profile for mTHPC. However, the drug and light dose that resulted in 50% cytotoxicity in the “normal” cell gave 85% cytotoxicity in the drug resistant cell (229,230). Such an effect has been noted frequently with PDT. Thus far most studies indicate that this is the result of a different localization of the drugs. For the MCF-7 cell line a more pronounced localization in lysosomes in the drug resistant strain was discussed (229,230). In vitro tests have also been performed with freshly prepared human gynecological tumors (breast, ovary and ascites) and indicated that individual treatment protocols might be required (231). Cell tests also indicated the utility of Foscan (and Foslip) for perihilar cholangiocarcinoma. Treatment of two biliary cancer cell lines gave a high phototoxic potential (LD90 600 ng mL−1 and irradiation with 1.5 J cm−2 (660 ± 10 nm). Both formulations gave similar localizations and similar PDT effects (232,233).

Other studies investigated the combined use of PDT and radiotherapy in human breast cancer cells (234), or effects on resistance against chemo or radiotherapy, which is not induced by PDT (200). Two cell lines resistant against poly-Hp or PPC were prepared through radiation. However, they showed no cross-resistance against mTHPC PDT (235). The results indicated that the mode of resistance depends to some extent on the nature of the PS.

For future applications it is also important to know the ability of neurons to survive. Here an interesting in vitro study compared the stability of neurons, satellite glia and human adenocarcinoma cells (236). The latter two were significantly more susceptible to Foscan PDT than the neurons. Even more importantly, Wright et al. identified conditions where no effect on the neurons was observed but the other two were killed. Thus, neurons in culture can survive mTHPC PDT under conditions sufficient to kill tumor cells and other nervous system cells. An intriguing model, based on the use of isolated nerve cells from a crayfish was developed by Uzdensky et al. (237). It allows the continuous recording of PDT-induced electrophysiological and biochemical properties. mTHPC was found to be highly effective in the nm range to abolish neuronal activity. It was much more effective than many chlorin e6 derivatives.

Individual cell phenotypes exhibit significantly diverse drug uptake and phototoxicity. A comparison of nine different biliary tract cancer cell lines identified two groups of cell lines with either high or low susceptibility to Foscan PDT (238). The high susceptibility ones were characterized by low cytokeratin-19, high vimentin and a high proliferative phenotype. This indicates the potential to identify suitable markers for the optimization of clinical cholangiocarcinoma treatment. Other related cell line studies are discussed below in the related sections on animal and clinical studies.

Animal models

Many animal models have been employed over the years. The first such report on hydroporphyrins was published by Bonnett et al. in 1989 (29). As in many other cases the use of animal models to predict effects in humans is problematic. Many studies have pointed out the varying biodistribution of Temoporfin in different animal species (137,239). Likewise, sometimes similar distribution but different photophysics are observed (240). In addition, such models are only of limited use for predicting the best conditions for clinical purposes. For example, a comparison of three different xenografts in mice showed different pharmacokinetics for the same drug/light dose (241). Thus, these systems can only serve to establish the basic conditions for further tests. Even with limited goals in mind the choice of the right animal model is critical for the utility of the in vivo tests. Here, orthotopic tumor models present the closest resemblance to the clinical situation with regard to PDT and a concise analysis of the PDT relevant models has been given by D’Hallewin et al. (242).

Table 2 summarizes most of the models and techniques used with mTHPC and related compounds. The following sections give only a brief overview on selected animal studies with Temoporfin.

Table 2.   Animal models used for mTHPC and related compounds.
Animal modelCompound/studyCommentsYearRef.
Arthritis, antigen induced murine arthritis in C57Bl/6 micemTHPC and other forms:
rheumatoid arthritis
mTHPC-PEG showed best accumulation in arthritic joints
PDT reduced arthritic score, good results were obtained at lower doses (0.05 mg kg−1) compared to cancer PDT
2008  445
Canine laryngeal edemamTHPC: Safety standards 1994  265
Canine (beagle)mTHPC: Prostate damageNecrosis of the glandular tissue with good healing1996  285
Canine, prostatemTHPC: Test of tolerance 1999  286
Carcinoma chemically induced in hairless mice (SKH-1)mTHPC: Tumor/normal skin ratio and comparison with HpDBest tumor/normal tissue ratio HpD 3.2, mTHPC 2.72000  250
Chick chorioallantoic membrane modelpTHPP in PGLA nanoparticlesPS remains longer in vascular compartment and vascular effects are enhanced2004  524
Chick chorioallantoic membrane modelFoscan, Foslip, Fospeg: Occlusion of neovascularizationPharmacokinetics similar for all; Foslip less photothrombic than Fospeg2006  287
Chick chorioallantoic membrane modelmTHPC: Cotreatment with antivascular endothelial growth factor drugsSynergistic effect2007  447
Colon adenocarcinoma induced in rats, Wistar/FurthmTHPC: Tissue localization study 1994  267
Colon adenocarcinoma (CC531) induced in rats, Wag/RijAmTHPC: Efficacy studiesTumor:tissue ratio >41997  278
Colon adenocarcinoma (CC531) induced in rats, Wag/RijAmTHPC: Distribution after i.v. versus i.p.IPPDT better than i.v.1997  266
Colon adenocarcinoma (CC531) induced in rats, Wag/RijAmTHPC-MD2000: Utility for liver tumorLoss of tumor selectivity with time, no advantage2000  478
Colon adenocarcinoma (CC531) induced in mice, Swiss CD1 nu/numTHPC: IOPDTThree times longer recurrence free time in model2000  269
Cottontail rabbit papillomavirus-induced tumors in rabbitsmTHPC: Nonrandomized control trial
0.3 mg kg−1, 6 days, λ = 652 nm
Seventy five percent cure rate of papillomas <100 mm21994  265
Cottontail rabbit papillomavirus-induced tumors in rabbitsmTHPC-MD2000: Pharmacokinetics30 mg kg−1, 2 × 75 J cm−2 after 6 and 10 days gave 58% cure rate; tumor/tissue = 4:11999  485
FelineBiodistributionSimilar to other species2000
2002
  390
  389
Feline, H&N SCCmTHPC: Vascular effectsStudy with power Doppler ultrasonography2006  254
Feline, H&N SCCmTHPC liposomal formulation: Pharmacokinetics 18 catsCR: 75% at 1 a
Side-effects: Mild local toxicity such as erythema and edema in 15% of the patients
Tumor recurrence rate: 20% with a median time to recurrence of 172.25 (±87.1) days
2007  292
Feline, SCC, pet catsmTHPC liposomes: PharmacokineticsmTHPC-LIP ≫ mTHPC, no side-effects2005  291
Fibrosarcoma (FsaR) in female C3H/HeN micemTHPC: Effect on poly(adenosine diphosphate–ribose) polymeraseStrong induction of enzyme with mTHPC and Photofrin2003  170
Fibrosarcoma (LSBD1) in BIX ratsmTHPC: PharmacokineticsTwo different phases of effect at 2 and 24 h2003  204
H&N SCC (HNX-OE) xenografted in BALB/c micemTHPC: Effect on vascular damagePDT effect mainly determined by early vascular response2005  206
Horse, equine sarcoidsmTHPC: Test of textile light diffuser 2006  293
Human adenocarcinoma xenografted in BALB/c micemTHPC and mTHPC-PEG: ComparisonEffect similar for both PS1998471,475
Human cervical SCC (SiHa) implanted in mice, NOD-scidmTHPC: Effect of adoptive immunotherapyImprovement2001  455
Human colon adenocarcinoma grafted onto Swiss nude micemTHPC-PEG: Tissue distributionMaximum tumor fluorescence after 24 h, tumor:skin ratio = 2.95, tumor:muscle ratio = 6.611997470
Human colon adenocarcinoma xenografted in CH3 micemTHPC: Uptake and histologyDifferent xenografts give different results at same drug/light dose1998241
Human colon adenocarcinoma (LS174T) injected in mice, Swiss nudemTHPC-MD5000: BiodistributionBetter tumor localization of mTHPC-MD5000 compared to mTHPC1998472
Human colon adenocarcinoma (HT29) xenografted in Swiss mice, nu/numTHPC: PDT studyBest results 24 h after drug administration1995219
Human colon adenocarcinoma (HT29) injected in rats, Swiss, nu/numTHPC: PDT studyHigher activity with lower irradiance1998100
Human colon adenocarcinoma (HT29) xenografted in Swiss mice, nu/numTHPC: Effect of vitamin E analog, TroloxEnhance PDT effect and delayed tumor doubling time2000454
Human colon adenocarcinoma (HT29) implanted in mice, NOD-scidmTHPC: Effect of adoptive immunotherapySignificant improvement2001455
Human colon adenocarcinoma (HT29) injected in ICFW nu/nu micemTHPC PLA nanocarriers: 2002481
Human colon adenocarcinoma (HT29) xenografted in Swiss mice, nu/numTHPC: Modality of cell death 2004165
Human colon adenocarcinoma (HT29) in NMRI nu/nu miceFoslipHigh concentration in tumor tissue after 4–8 h
Average tumor/muscle selectivity = 6.6
Tumor/skin selectivity: 2
2007505
Human colon adenocarcinoma (HT29) injected in mice, NMRI, nu/numTHPC invasosomesSmaller tumor growth, pilot study2008517
Human colon adenocarcinoma (HT29) injected in female BALB/cAnN.Cg-Foxn1nu/CrlNarl miceMicellar formulation of mTHPCSimilar PDT effect to free drug but less skin phototoxicity2010532
Human colon adenocarcinoma (WiDr) injected BALB/c nude micemTHPC: Effect of glucose and TCooling to 5°C and glucose administration enhance PDT1999 96
Human hypercalcemic small cell carcinoma of the ovary xenografted in ICR nu/nu:Zur micemTHPC: PDT studySeven times more necrosis in IPDT treated tumors compared to control tumors1999279
Human malignant melanoma in athymic micemTHPP: Localization and PDTTwo effects: Direct phototoxicity and vascular injury1990 35
Human malignant mesothelioma implanted in BALB/c nude micemTHPC: Test of drug-light intervalBest results with 3 days interval1993148
Human malignant mesothelioma implanted in BALB/c nude micemTHPC: Test of therapeutic indexBest results with up to 5 days interval and increased doses of light1993149
Human malignant mesothelioma implanted in BALB/c nude micemTHPC: PDT and comparison with mTHPC-MD5000Tumor necrosis: mTHPC-MD5000 ≫ mTHPC after 4 days1997257,475
Human malignant mesothelioma (H-meso-1) xenografted in CH3 micemTHPC: Uptake and histologyDifferent xenografts give different results at same drug/light dose1998241
Human malignant mesothelioma (H-meso-1) xenografted in nude micemTHPC: PDTBest response after 24 h, strong dependence on drug-light interval but not on fluence rate2001259
Human malignant mesothelioma (H-meso-1) xenografted in nude micemTHPC: Uptake and biodistribution 2003258
Human malignant mesothelioma (H-meso-1) implanted in BALB/c nude micemTHPC: Effect of PDT on hypoxiaInconclusive results2003396
Human malignant mesothelioma (H-meso-1) xenografted in nude c1nu/nu micemTHPC-MD2000: PDTSame PDT effect as mTHPC but no skin or muscle damage2003482
Human malignant mesothelioma implanted in c1/nu/nu micemTHPC-MD2000PDT effect similar to mTHPC but lower skin phototoxicity2007  486
Human oral SCC xenografted in CH3 miceComparison of mTHPC-PEG and mTHPCmTHPC ≫ mTHPC-PEG2001  252
Human retinoblastoma, female Swiss nu/nu mouse xenografts, RB102-FER, RB109-LAK, RB111-MILmTHPCSignificant PDT effect in one cell line (RB111-MIL)2010  438
Human SCC (xf-354) xenografted in rag-2 micemTHPC: Uptake and histologyDifferent xenografts give different results at same drug/light dose1998  241
Human SCC xenografted in BALB/c micemTHPC; mTHPC-PEG: ComparisonLarger tumor necrosis with mTHPC-PEG1998471,475
Human SCC (xf-354) xenografted in rag-2 micemTHPC; mTHPC-PEG; Photofrin: ComparisonmTHPC and Photofrin effective, mTHPC-PEG only effective with cyanurchloride linker2001  251
Human tumor LOX in nude micemTHPP: Localization 1990
1991
   34,
   37
Intracranial carcinoma (VX2) implanted in rabbits, New Zealand whitemTHPC: Effect on apoptosisApoptosis detected after 24 h2000  187
Mammary carcinoma (mouse CaD2) implanted in C3D2/F1 micemTHPC: Uptake, localization and PDTmTHPC ≫ mTHPP1995  120
Mammary carcinoma in male transgenic mice, strain FVB/NTgN(WapHRAS)69Lln YSJLmTHPC-MD2000: Apoptosis effectsMice express the human RAS gene
Cytokeratin 18 cleavage is an early PDT response
2006  489
Mice mammary carcinoma (C3H)mTHPP: o,m,p-isomers effect on normal musclemTHPP is most selective1992   32
Mice, BALB/cmTHPP: Photobleaching 1996   89
Mice, BALB/cmTHPC: PharmacokineticsNeither lipoprotein levels nor cholesterol metabolism affects the pharmacokinetics of mTHPC in plasma2007  107
Mice, C3H/Hen Af-numTHPC: Evaluation of bladder damageModerate to severe bladder response with complete healing within a few weeks1996  273
MinipigsmTHPC: Effect on intrathoraic tissue; comparison with mTHPC-MD5000Severe damage with mTHPC, none with mTHPC-MD50001997  257
MinipigsmTHPC; mTHPC-PEG: Endobronchial PDTUlceration and necrosis of bronchial mucosa for mTHPC but not for mTHPC-PEG1998  471
MinipigsmTHPC-MD2000: Expleural pneumonectomy followed by IOPDTFeasible method and well tolerated in animals2003  482
Mouse (Line 1) lung adenocarcinoma in BALB/c micemTHPC: Effect of immunostimulantsGlycated chitosan as immunoadjuvant raises cure rate from 0% to 37%2005  457
Mouse glioma (VMDk)mTHPPBasic PDT study1991   36
Mouse Lewis lung carcinoma (LLC) in C57BL/6 micemTHPC: Complement activationStreptokinase increases PDT efficacy2004  456
Mouse Lewis lung carcinoma (LLC1) in male C57BL/6 micemTHPCInitial reduction of tumor, but regrowth after 9 days2010  268
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: PDT effect on NaGalase activityEnzyme level is reduced to background level1998  169
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Effect of adjuvant mycobacterium cell-wall treatmentSingle treatment enhances PDT effect1998  210
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Effect of adoptive immunotherapyImprovement2001  455
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Effect of BCG immunotherapyEnhances cure rates2001  256
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Effect on neutrophile responsePronounced neutrophila after PDT2001  211
Mouse mammary sarcoma (EMT6) in BALB/c mice transfected with plasmid pR70/GFPmTHPC: Effect on heat-shock proteinsPDT activated heat-shock protein 70 promoter in a model system2003  175
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Tumor distributionTemporally and spatially heterogenous2005  122
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Effect of immunostimulantsGlycated chitosan as immunoadjuvant raises cure rate from 38% to 75%2005  457
Mouse mammary sarcoma (EMT6) in BALB/c miceFoslipPartial cure 24 h postinjection2008  503
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: DosimetryPDT dosimetry does not correlate with singlet oxygen production2008  141
Mouse mammary sarcoma (EMT6) in Foxn1 nu/nu miceFoslip: Pharmacokinetics and PDT effectHighest tumor/muscle ratios after 6 and 15 h
Best tumor response after 6 h when mTHPC was present in both endothelial and parenchyma cells
2009  506
Mouse mammary sarcoma (EMT6) in BALB/c micemTHPC: Apoptosis and drug applicationFractionated double injection of mTHPC results in 100% cure2010  135
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPC: Tissue localization study 1995  134
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPC: Distribution and excretion[14C]-labeled mTHPC gives an elimination half-life of 10–12 days1996  126
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPC: PDT studyAfter 70 days: 25% tumor recurrence in treated group compared to 80–90% in control group1997   45
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPC: Comparison of tumor and muscle damageDevelopment of an animal model for testing of PDT effects1997  271
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPC-PEGs: PDTLimited utility1999  573
Murine colorectal carcinoma (Colo 26) implanted in BALB/c micemTHPBC: PDTPhotodynamic threshold of 0.6 mg kg−12000  490
Murine colorectal carcinoma (Colo 26) implanted in Swiss nu/nu micemTHPC: PharmacokineticsAccumulation in leukocytes fits PDT efficacy2004  205
Murine glioblastoma (C6) injected in rats, Sprague–DawleymTHPC: Uptake of 14C-labeled PSSuggests mTHPC for PDT and ALA for PDD1998281,418
Murine glioblastoma (C6) injected in rats, WistarmTHPC: Intratumoral administrationIntratumoral administration gave similar results to systemic administration. However, optimum concentration is already attained after 4 h2008  282
Murine hepatoma (MH22A) in BDF1 hybrid micemTHPC: Effect of coadministration of doxorubicinCoadministration better effect than either treatment alone2006  461
Murine leukemia in mice (L1210)mTHPC: + chemotherapy (navelbine or cisplatin) + immunotherapy (immune lymphocytes)Significant synergistic antitumor effect2010  462
Murine Rifi tumor induced in C3H/Km micemTHPC: PDT in combination with mitomycin CLower light doses can be used for same PDT effect when using mTHPC together with mitomycin C1995  202
Murine Rifi tumor induced in C3H/Km micemTHPC; Photofrin: PDT, comparisonGood results with 0.15 mg kg−1, 1 day, λ = 652 nm, much better than Photofrin and more rapid skin clearance1995  255
Murine Rifi tumor induced in C3H/Km micemTHPC: Influence of light fractionation and fluence rateFractionation of light with short dark times can improve PDT1996  152
Murine Rifi tumor induced in C3H/Km micemTHPC: Uptake and pharmacokineticsStronger correlation between plasma level and effect than tumor uptake and effect1997  106
Murine Rifi tumor induced in C3H/Km micemTHPC: PharmacokineticsmTHPC plasma level correlated with effect1997  106
Murine Rifi tumor induced in C3H/Km micemTHPC: Effect on hypoxiaPDT results in oxygen depletion and increase in relative hypoxia2003  396
Murine SCC (SCCVII) in C3H/HeN micemTHPC: Effect of complement activationZymosan increases PDT efficacy2004  456
Murine SCC (SCCVII) in mice, C3H/HeNmTHPC: PDT effect on NaGalase activityEnzyme level is reduced to background level1998  169
Murine SCC (SCCVII) in mice, C3H/HeNmTHPC: Effect on neutrophile responsePronounced neutrophila after PDT2001  211
Murine SCC (SCCVII) in mice, C3H/HeNmTHPC: Effect on neutrophile response 2002  212
Murine SCC (SCCVII) in mice, C3H/HeNmTHPC: Effect of ceramide analogsSphingolipids can serve as biomarkers for PDT response2011  458
Nonmelanoma skin carcinomas in SKH-1 micemTHPC: Thermogel formulationGood tumor:tissue selectivity2006  247
Pancreatic carcinoma (PC-1) implanted in Syrian hamstermTHPC: PDT study of pancreatic cancer modelLarger volumes of tumor necrosis compared to other PS1997  276
Papillomas chemically induced in hairless mice (SKH-1)mTHPC: Determination of tumor/normal skin ratio and comparison with HpDBest tumor/normal tissue ratio |HpD 6.2, mTHPC 5.11997  249
PigsmTHPC: PDT effect on normal tracheaDamage confined to mucosa and submucosa, recovery within 14 days with 0.15 mg kg−1, 4 days, λ = 652 nm, <50 J cm−21999  261
PigsmTHPC: IPDT normal lung parenchymaGood potential2001  262
PigsmTHPC: Effect of octreotideSuppresses severity of PDT effect
After PDT + octreotide: 28.5% full-thickness necrosis, PDT alone: 71.4%
2004  463
Plasma cell tumor (PC6) induced in BALB/c miceo,m,p-THPC isomers and mTHPBC: ComparisonFirst in vivo tests1989   29
Plasma cell tumor (PC6) induced in BALB/c micemTHPC: Cost–benefit analysismTHPC superior to other PS1993  215
RabbitmTHPC: Safety standardsSkin study1994  265
Rabbit, white male New ZealandmTHPC: IOPDT effect on blood vessels and nervesNo clinical symptoms2003  288
Rat colon adenocarcinoma (CC531) induced in WAG/RjjA ratsmTHPC: Treatment of liver metastasesEighty-seven percent tumor free after 28 days1999  270
Rat colon adenocarcinoma (CC531) induced in WAG/RjjA ratsmTHPC-MD2000: Pharmacokinetics 2000  478
Rat colon adenocarcinoma (CC531) induced in WAG/RjjA ratsmTHPC: Immunological effects of PDTNo antitumor effect of a systemic immune response2003  214
Rat epithelial ovarian cancer (NuTu-19) in Fischer 344 ratsmTHPC-PEG: Pharmacokinetics and selectivitymTHPC-PEG selectivity best after 8 days; pelvic debulking model1999  280
Rat epithelial ovarian cancer (NuTu-19) in Fischer 344 ratsmTHPC-PEG: IPDTSuitable for debulking of pelvic cancer1999  474
Rat fibrosarcoma (MC28) in Lister ratsmTHPC: Optimization of light conditionsFractionated or low power light better2002  156
Rat malignant mesothelioma (IL-45) implanted in Fischer 344 ratsmTHPC: IOPDT of the chest cavityPneumonectomy followed by PDT gave fatal complications2005  263
Rat malignant mesothelioma (IL-45) implanted in Fischer 344 ratsmTHPC; Verteporfin: ComparisonVerteporfin > Foscan2006  263
Rat metastatic mammary carcinoma (DMBA-4) in Wistar–Furth ratsmTHPC: Effect of immunostimulantsGlycated chitosan as immunoadjuvant raises cure rate from 0% to 9%2005  457
Rats, WAG/RjjAmTHPC: Toxicity studySimilar toxicity profile as Photofrin1994  150
Rats, WAG/RjjAmTHPC: Comparison of red and green light in IPPDTIntestinal damage is dose limiting for IPPDT with red light1997  151
Rats, WistarmTHPC: Uptake and localization in adrenal glandOnly steroid synthesizing cells show PS-induced fluorescence1998  284
Rats, WistarmTHPC: Fine-needle IPDLesions heal safely1999  260
Rats, WistarmTHPBCLiver necrosis shortly after administration, none after 72 h, larger areas of necrosis compared to mTHPC or Photofrin2000490,493
Rats, Fischer 344mTHPC-PEG: PDT normal tissueNo adverse effects within the required PDT dose2000476
Rats, FischermTHPC: Photobleaching in skinPhotobleaching kinetics different from O2 changes200291
Rats, WistarmTHPC: Concentration in ex vivo samplesProtocol for determination with Solvable as a tissue solubilizer2008128
RatsmTHPC: In vivo quantificationFluorescence differential path length spectroscopy showed good correlation with chemical extraction2009553
Rats, WistarmTHPC: Monitoring institial PDT during treatmentFluence (rate), fluorescence, hemoglobin oxygen saturation, and blood volume could be monitored during PDT without interruptions to the therapeutic illumination200955
SheepmTHPC: Test of mucosal ablationSevere complications with green light in esophagus, suggests use of blue light2003276
Sheep, Swiss alpine whitemTHPC: Pharmacokinetics; model for esophageal cancerModel for precursor lesions of esophagus adenocarcinoma
mTHPC pharmacokinetics similar in humans and sheep
2009277
SCC induced in Syrian hamster cheek pouchesmTHPC: Uptake and clearance 1995567
SCC induced in Syrian hamster cheek pouchesmTHPC: Effect of fluence rate 1996155
SCC induced in Syrian hamster cheek pouchesmTHPC: Tissue localization studyUtilization of ex vivo fluorescence spectroscopy for pharmacokinetic study1996121
SCC induced in Syrian hamster cheek pouchesmTHPC: Drug-light interval studyLight treatment 4–8 days after drug administration best1997127
SCC induced in Syrian hamster cheek pouchesmTHPC: Wavelength dependency studyOptimum range is λ = 647.5–652.5 nm1997243
SCC induced in Syrian hamster cheek pouchesmTHPC: Determination of threshold for muscle damage during interstitial PDT 1998244
SCC induced in Syrian hamster cheek pouchesmTHPC: Tissue localization study and comparison with BpD monoacidBpD more selective2000245
SCC induced in Syrian hamster cheek pouchesmTHPC: PharmacokineticsLimited utility of hamster model for clinical applications2000240
SCC induced in Syrian hamster cheek pouches14C-mTHPC: Uptake and localization 2002246
Syrian golden hamstermTHPC: Tissue localization studyNormal tissue in the pancreas region tolerate PDT1996325,422

Skin.  Many studies on squamous cell carcinoma used a SCC hamster model (121,127). Although obvious from a chemical viewpoint, the same model was used to determine the range of λ = 647.5–652.5 nm as the most effective wavelength range for PDT (243). A determination of the threshold of muscle damage (1-3J) during interstitial PDT (IPDT) showed that 85% of the SCC tumor could still be destroyed under these conditions (244). A comparison with BpD showed that this drug localizes to a smaller extent in the smooth muscle and is cleared more rapidly indicating some advantages for using BpD (245). However, a comparison of the pharmacodynamics of normal hamster and human mucosa indicated that this model is limited in its use for clinical predictions but has value for preclinical screenings (240). Earlier localization studies based on fluorescence spectroscopy were confirmed using 14C-labeled mTHPC (246). Skin cancer offers itself to topical applications. Thus, an initial study of a mTHPC thermogel formulation after topical application on hairless SKH-1 mice bearing nonmelanoma skin carcinomas showed good tumor:tissue selectivity (247). The highest PS concentration in tumor was observed 6 h after drug application while no drug was detected (248) in normal tissues or plasma after topical drug application. A study using a hairless mice skin papilloma model indicated that HpD can give a slightly higher tumor/normal skin tissue ratio than mTHPC, but the latter reached its peak at a lower dose (249). The related carcinoma cells showed lower but similar tumor/normal skin ratio for both PS (250).

Head & neck.  Several animal model studies were performed for H&N cancers (251). Human oral SCC cells xenografted in mice gave a good response to mTHPC (252). Analysis of a series of human keratinocyte cell lines derived from human SCC gave interesting results with regard to the regulation of invasion promoting tumor factors. Exposure to sublethal PDT doses showed that both active and latent MMP-2 and MMP-9 were down-regulated in some cell lines (UP, VB6) while H376 showed an increase in active MMP-2 (253). Thus, while there is clearly potential for using this for predicting PDT outcomes the divergent results for different cell lines indicate the need for further studies. In terms of detection one study, with cat H&N SCC, showed that the vascular effects of PDT could be followed with power Doppler ultrasonography (254).

Chest.  Breast cancer carcinoma implanted in mice was effectively treated with mTHPC and the chlorin was much more effective than the porphyrin mTHPP (120). A comparison with Photofrin for treatment of a murine cancer clearly showed mTHPC to be the better PDT agent and to have a more rapid skin clearance (255). The same PDT effect could be obtained with lower light doses when the drug was administered together with the bioreductive agent mitomycin C (202). This animal model also revealed the possibility to improve the PDT effect through light fractionation (152). Use of labeled mTHPC showed that the drug concentration in the tumor was highest after 24–48 h (106). Surprisingly, the best tumor response was achieved 1–3 h after drug administration when the drug tumor concentration had not yet reached its highest value. Bacillus Calmette-Guérin (BCG) vaccine administration was found to enhance the cure rate for mouse mammary carcinoma. Interestingly, this effect was still observed when the BCG injection was given 7 days after the PDT treatment, i.e. it effects events involved in preventing tumor recurrence (256).

Early studies with human malignant mesothelioma implanted in nude mice established the basic therapeutic conditions (148,149) and also indicated better effects with mTHPC-MD5000 (257). For example, these studies showed the importance of the drug-light interval and the light dose (149). Detailed studies of a human mesothelioma xenograft showed a marked difference between tumor or skin drug level and PDT effect and between tumor drug level and optimum drug-light interval (258). Preclinical studies showed a strong dependence of the PDT effect on the drug-light interval but not the fluence rate (259). In addition, the PDT effect could be enhanced by an increase in tumor oxygenation through carbogen breathing or nicotinamide injection.

IPDT was shown to give zones of necrosis in the normal lung that heal safely, indicating potential for PDT treatment of lung cancers (260). An endobronchial study with pigs showed that PDT of the trachea results in atrophy and acute inflammation of the epithelium and the submucosal glands. Using fluences of 50 J cm−2 or less, full recovery occurred in 14 days (262). Initial pharmacokinetic data indicated that the drug level was the same in the trachea at Day 6 and 20. Nevertheless, significant interanimal variation was found indicating the necessity of optimum dosimetry. A comparison of laser photocoagulation and IPDT of normal pig lung parenchyma showed that both techniques offer good potential, with the latter giving better healing (262). An attempt to use intraoperative PDT (IOPDT) of the chest cavity for malignant pleural mesothelioma failed. All rats treated with pneumonectomy followed by spherical PDT died within 48 h (263). A comparison of Foscan and Verteprofin intracavitary PDT on local malignant mesothelioma in the mediastinum of syngenic rats showed that both PS can be used. The PDT effect of verteporfin was better (264).

Similar results were obtained with papillomavirus-induced tumors in rabbits (297). The canine laryngeal edema was used as a model to define safety standards for drug use within the airways (265). Intraperitoneal PDT (IPPDT) of rats was used to establish the basic toxicity profile, which was similar for both mTPHC and Photofrin (150). A comparison of red and green light illumination indicates the latter might be better for IPPDT treatment, however, it is limited by the ineffective light distribution in the peritoneum (151). Nevertheless, IPPDT results were better than i.v. applications (266).

Induced adenocarcinoma was used to determine the tissue distribution in rats and indicated a significant difference between tumor and muscle tissue (267). This early study indicated that abdominal or thoracic treatment might be better performed with longer drug-light intervals. Lewis lung carcinoma was studied in a mouse model and gave initially good results, inhibited tumor growth and prolonged mice survival. However, tumor growth was regained after 9 days (268).

Gastrointestinal tract.  A mouse model showed the utility of adjuvant IOPDT (AIOPDT) for colon cancer (269). Application of 0.3 mg kg−1mTHPC, 3 days incubation followed by total tumor resection and then followed by illumination (λ = 652 nm, 5 J cm−2) gave an increase of the time to tumor recurrence from 11.4 to 33.3 days. Likewise, colon adenocarcinoma induced in the rat liver was used to study the potential for PDT on liver metastases. Different pharmacokinetics were found for the liver and tumor tissue with the former rapidly being cleared of the drug. PDT under standard conditions gave 87% tumor free animals after 28 days indicating that this modality might be able to induce complete tumor remission of liver tumors (270). Fractionated light application or lower light fluences improved the PDT effect (156). In another study with murine colorectal cancer implanted mice it was shown that the highest tumor:tissue ratios after 4 days were found for the small intestine, liver and skeletal muscle (134). This animal model was used as a general test bed for PDT assessment (271) and for AIOPDT (45). A study of healthy hamsters showed highest drug levels in the gastric and duodenal mucosa and acinar pancreas after 2–4 days (272). Except for the duodenum all lesions healed safely. Similarly, intravesical PDT in normal mice resulted in moderate to severe functional bladder damage with full recovery within a few weeks (273). The utility of treating pancreatic cancer in animals was shown with a hamster model (274).

One of the first animal studies related to esophageal cancer used a sheep model (275). A test of mucosal ablation through PDT in normal animals revealed significant complications in the esophagus following illumination with green light (514 nm) especially at high doses (276). Blue light irradiation (412 nm) resulted in significantly less damage. Clearly treatment of the precursor lesions of esophagus adenocarcinoma would be an optimum treatment choice. However, here an appropriate animal model was lacking. A thorough study of sheep treated with mTHPC showed that this might serve as such a model (277). The plasma pharmacokinetics were similar in sheep and humans, with Foscan reaching its maximum at 10 h post i.v. Two days after injection it was mainly distributed in the lamina propria, followed by a penetration into the epithelium. The sensitivity of both sheep and human tissue to mTHPC PDT was similar. Use of rodents as models for esophageal cancer is problematic as they do not allow a study of stricture side-effects. Thus far, pigs might be the best choice for related PDT studies (278).

Ovary.  A rat model for the study of peritoneal cancer gave a promising tumor:tissue ratio of greater than four (267). Likewise, both superficial irradiation and IPDT of mTHPC treated hypercalcemic ovary small cell carcinoma in a mouse xenograft model gave good results (279). A NuTu-19 ovarian cancer rat model was developed and used for testing debulking techniques. Use of mTHPC-PEG gave a very high (40 ± 12) tumor/tissue ratio after 8 days (280).

Brain.  Most studies in this area have focused on ALA PDT and its effect on the blood brain barrier. Initial tests with Temoporfin in this area indicated less skin toxicity than other PS and effective cytotoxicity at a wavelength of 652 nm and light doses of up to 20 J cm−2. The tumor/normal brain tissue ratio was 20:1 (120,219). A first study of the pharmacokinetics of 14C-labeled mTHPC was performed using a rat glioma model (281). A rabbit model showed induced apoptosis as a result of several PS (187). A comparison of intratumoral administration and systemic one showed that both result in complete tumor localization in a C6 rat model. However, intratumoral administration gave an optimum drug dose already after 4 h postadministration (282).

Other.  A first rat study showed that the adrenal gland can take up PS and indicated the possibility for treating medullary neoplasia (283). Interestingly, only steroid synthesizing cells of the adrenal gland exhibited an intense photosensitizer-induced fluorescence after administration (284). Treatment of the prostate was evaluated in beagles and showed a good localization of the drug in the prostate within 2–3 days. Significant areas of glandular tissue could be necrosed with good healing (285) although regeneration of urethral epithelium could take up to 3–4 days (286). Various Temoporfin formulations were evaluated for the treatment of choroidal neovascularization associated with age-related macular degeneration (287). Possible side effects of IOPDT on blood vessels and nerves were assessed in rabbits (288). PDT at high drug concentrations (0.3 mg kg−1) and light doses (20 J cm−2) led to necrosis of all illuminated tissue. At lower concentrations the blood vessels showed severe edema, media hyperplasia or loosening of the endothelial layer, but no damage of the vessel wall or rupture was observed. Nerve cells underwent 75% demyelization, however, without clinical symptoms. Thus IOPDT was suggested as a safe treatment option.

Veterinary applications

Only few specific studies have addressed veterinary applications of PDT. This is surprising as the regulatory process is less involved and the related drug development cheaper. With the increasing willingness of individuals to spend significant amounts of money on pet health care this area offers potential for industry. One study investigated the biodistribution of mTHPC in cats and found a situation similar to other species and no clinical or pathological changes attributable to the drug (289). Likewise, the time necessary for maximal accumulation in various feline tissues has been determined (290). Thus, Foscan PDT might be a good treatment protocol for feline neoplasm, e.g. SCC. Here, mTHPC-LIP was found to be superior to standard mTHPC (291). An in vivo study with 18 cats showed a complete remission (CR) of 75% after 1 year (292). The only application in the equestrian area was the test of a novel light diffuser during the treatment of equine sarcoids (293).

Clinical experience

Apart from Photofrin, Foscan is the only other photosensitizer approved for use in systemic cancer therapy. Various derivatives of ALA (e.g. Levulan and Metvix) have also received approval as sensitizers for topical applications, meaning they are at present limited to skin cancers but with a high degree of success (294). Additionally, Verteporfin must be mentioned here. Developed as a photosensitizer for light-activated treatments it was successfully used for the treatment of age-related macular degeneration (295,296). Excellent overviews of recent advances in the clinical field concerning these established PS were published in 2004 (297,298) and newer treatises are available as well (299,300). The clinical impact of mTHPC and other PS in the treatment of gynecological diseases and head & neck cancer has been discussed (301–303). Reviews on skin cancer (basal cell carcinoma [BCC]) (304) as well as gastrointestinal and esophageal (305–308), brain (309), prostate (9,310), pancreas (311), breast (312), urological malignancies in general (313,314) and new treatment options thereof (315) and gynecological (316) malignancies show that these cancers can be treated with a reasonable degree of success with Temoporfin. A review by Konan et al. has surveyed the drug delivery and formulation aspects of drugs used for PDT (143). Table 3 summarizes details about the various clinical studies available for Foscan and related drugs and formulations.

Table 3.   Selected clinical studies.
Cancer typeTreatmentConditionsSample size*Result/tumor response†Side-effects/commentsYearRef.
  1. *Number of protocol compliant patients. †Unless specified otherwise to mean complete tumor response.

Anal intraepithelial neoplasia, Grade IIIFosgel0.75 mg kg−1mTHPC, 8 h, λ = 652 nm, 50 mW cm−2, 20 J cm−2, 2 × treatment after 7 days9No responseNo effect attributed to limited penetration in AIN III2009440
Bile duct: Malignant biliary strictures, irresectablemTHPC0.15 mg kg−1mTHPC, 3 days13Median survival time 21 months (10–56) compared to 8 months (1–43)Complications: 2 cholangitis with 1 fatal liver abscess, 2 haemobilia with 1 death from gall bladder empyema2007433
Brain: Intraoperative fluorescence guided resection, PD and PDTIntraoperative fluorescence guided resection, PD and PDT with mTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−2 for superficial irradiation, 90–140 J cm−2 for interstitial irradiation22Test as diagnostic tool: 88% sensitivity, 96% sensitivity138 tumor samples from 22 patients2001338
Brain: Malignant brain tumor, intraoperative fluorescence guided resection, PD and PDTIntraoperative fluorescence guided resection, PD and PDT with mTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−2, intraoperative fluorescence λ = 370–440 nm25Seventy-five percent radical resection with fluorescence guidance, 52% in control
Median survival 9 versus 3.5 months in control
Side effects: 2 severe phototoxic reactions due to unintentional exposure to direct sunlight, 1 transitional brain swelling2006419
Breast: Locoregional breast cancermTHPC0.10 mg kg−1mTHPC, 2 days, λ = 652 nm, 5 J cm−2
0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 10 J cm−2
3
4
Complete response in all patients with both protocolsHealing times 8–10 weeks
One patient delayed healing time and severe pain due to large treatment area
2001407
Chest: Malignant mesotheliomamTHPC
IOPDT
0.3 mg kg−1mTHPC, 2 days, λ = 650 nm, 10 J cm−2410 mm deep tumor infarctionSevere chest pain, 1 death from aspiration pneumonia
Two patients had preliminary PDT
1991390
Chest: Malignant mesotheliomamTHPC IOPDT
Phase I
0.3 mg kg−1mTHPC, 2 days, λ = 650 nm, 10 J cm−2810 mm deep tumor infarctionPDT after thoracotomy and surgical tumor resection1996397
Chest: Pleural mesotheliomamTHPC IOPDT
Phase I
0.1 mg kg−1mTHPC, 4 days, λ = 652 nm, 10 J cm−25Eighty percent after 9–11 monthsMaximal surgical resection followed by IOPDT1997399
Chest: Pleural mesotheliomamTHPC IOPDT
Phase I/II
0.075 to 0.15 mg kg−1mTHPC 4–6 days before complete surgical resection, then λ = 652 nm, 10 J cm−228Median survival time: 10 months for all patients.
Local tumor control: 50% 9 months after IPDT
 2001401
Chest: Pleural mesotheliomamTHPC IOPDT
Phase I
0.1 mg kg−1mTHPC 4–6 days before complete surgical resection, λ = 652 nm, 5/10 J cm−226Dose-limiting toxicity: 0.15 mg kg−1mTHPC. Three patients died in the perioperative period, one death directly related to PDTExtrapleural pneumonectomy: Seven patients; lung-sparing pleurectomy-decortication: 19 patients followed by PDT
Side effects: Systemic capillary leak syndrome leading to death in two of three patients treated at the highest dose; wound burns and skin photosensitivity
2003400
Chest: Malignant pleural mesotheliomamTHPC
Phase I
0.1 mg kg−1mTHPC, 6 days, λ = 652 nm, 10 J cm−2
IOPDT after thoractomy and pleurectomy or extrapleural pneumonectomy
9Variable, main interest was interleukin levelsDose-limiting toxicity: 0.1 mg kg−1mTHPC, 4 days, λ = 652 nm, 10 J cm−2 (death in 2/3 patients through systemic capillary leach syndrome, hypertension, adult respiratory distress syndrome)2003402
Chondrasarcoma of the hyoidmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−21Two PDT treatments within 1 a, good resultsCase report2009360
GI: Aerodigestive tract: Early SCC of the upper aerodigestive tractmTHPC
Phase I/II
0.15 mg kg−1mTHPC, 4 days, λ = 652/514 nm27
        4
Eighty-three percent of early tumors in remission after 15.3 months
Twenty-five percent complete response for T1 and T2 cancer
Side effects with red light: 1 bronchial stenosis, 1 esophagotracheal fistula, 2 probable occult perforations of the esophagus; none with green light
Skin photosensitization in 12 patients for 1 week
1996382
GI: Early esophageal cancermTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652/514 nm35 tumorsSeventy-seven percent disease free 3–38 monthsSome side effects with 652 nm light, none with 514 nm light1996373
GI: Early SCCmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652/514 nm, 100–150 mW cm−2, 7–16 J cm−225Eighty-five percent after 14 monthsPatients previously treated for H&N cancer
SCC from esophagus, bronchi and mouth
1997375
GI: Early esophageal cancermTHPCn/d24 (8)Eighty-four percent cure rate after 2 aComparative study with Photofrin and HpD1998376
GI: Early esophageal cancermTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652/514 nm, plus other variations64 (59)Seventy-six CR for all PSComparative study with Photofrin and HpD, no significant difference between the PS. Complications: Three esophagotracheal fistulae, 2 esophageal stenoses, three bronchial stenoses1999374
GI: Barrett’s esophagus and high-grade displasiamTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 8–20 J cm−27Elimination of columnar-lined esophageal mucosa, reduction in length of Barrett’s segment or downgrading of the dysplasia in all patients
Patient with esophageal carcinoma CR at 27 months
Utility of Paterson lamp2002384
GI: Barrett’s esophagus: Early stagemTHPC0.15 mg kg−1mTHPC, 4 days, λ = 514 nm (100 mW cm−2), 75 J cm−212One hundred percent after 12–68 monthsModerate severity: One stricture2004386
GI: Barrett’s esophagus: Early stagemTHPC
Phase I
0.15 mg kg−1mTHPC, 3 days, λ = 652/511 nm193/4
4/6
Seven patients with high-grade dysplasia
Twelve patients with early esophageal cancer
Side effects: 1 death and 1 serious complication from taking biopsies too early; 2 esophageal strictures
2005387
GI: Rectal villous adenomasmTHPC0.15 mg kg−1mTHPC, 2/4 days, λ = 650 nm, 10–15 J cm−2260–80% reduction in sizeComparison with ALA and Photofrin, photosensitivity for 5 weeks1998568
GI: Superficial gastric cancermTHPC
Phase I/II
0.075 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−222Seventy-three percent complete remission 12–20 months
Eighty for intestinal type cancer
Fifty for diffuse Lauren’s carcinoma
Side effects: Mild-to-moderate photosensitivity, local pain for 1–2 weeks1998420,421
Gynecological malignancies: Ovary, recurrent carcinomamTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 5 J cm−23No relapse after 2 aTwo patients PDT by laparoscopy, one patient additional palliative debulking of metastatic tumors1997409
Gynecological malignancies: Ovary, terminal cancermTHPC IOPDT
Phase I
0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 5 J cm−28Seven of eight patients improved or no effect
Six patients free of relapse
All patients treated with all conventional methods before
Two patients died due to other complications
1997410
Gynecological malignanciesmTHPC0.15 mg kg−1mTHPC, 4 days, then λ = 652 nm, 20 J cm−24Survival: 3–4 monthsVarious pretreatments, wound healing delayed1999412
Gynecological malignancies: Vulval intraepithelial neoplasia (VIN III)mTHPC0.1 mg kg−1mTHPC, 4 days, λ = 652 nm, 10 J cm−26Complete response after 2 a (after 6 months a second PDT or excision was necessary in two patients)Side effects: Severe pain in two patients; all patients developed oedeme, one patient developed cellulitis2004413
Gynecological malignancies: Vulval intraepithelial neoplasia (VIN III), severe atypiamTHPC0.05 mg kg−1mTHPC, 1 day, λ = 652 nm, 40 J cm−21CR after 6 monthsCase report2008414
H&N: VariousmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−215Good resultsPreliminary studies with 1 a follow-up1995330
H&N: Oral cancer, SCC of the soft palateCase study0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 100 mW cm−2, 20 J cm−21Healing complete after 2 months, CR at 16 monthsSignificant pain and edema; Case study1996321
H&N: Oral cancer (some with field change disease)mTHPC0.15 mg kg−1mTHPC, 72–96 h, λ = 652 nm, 250 mW cm−2, 5–20 J cm−219Hundred percent single lesions up to stage T3 cleared after one treatment ca 60% patients with field change diseaseTongue tethering in a patient and necrosis in normal areas due to the light scattering1997336
H&N: Oral cancermTHPCStudy on dosimetry18In situ dosimetry is recommended1999329
H&N: SCC and BCCmTHPC0.10/0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 5–20 J cm−21892.7% after 3–24 months (mean 15 months)Good cosmetic outcome, high patient satisfaction1999335
H&N: Oral cancer, primary lip cancermTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 100 mW cm−2, 20 J cm−225Ninety-six percent after 12 weeks
Two cases of tumor recurrence after 4 and 18 months
One case lymph node metastasis after 7 months
One patient with lymph node metastasis, five patients with photosensitivity, sideeffects: Swelling and local pain
Excellent functional results; cosmetic results better than after surgery
2001337
H&N: Oral cancer; T1–T2 N0 tumors of the oral cavity and/or oropharynxmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−225Eighty-six percent after 37 months (mean follow-up)
CR for T1 lesions 95%, for T2 57%
For the four recurrences, salvage was achieved by conventional therapy
Moderate pain for a few days
2003333
H&N: SCC, T1–T3 stagesmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−221Ninety percent at 20.3 (mean follow-up)Heterogenous group with oral cavity, nasal, oropharyngeal, hypopharyngeal and laryngeal malignancy
Twenty-four percent required surgery for local recurrence or dysplasia after PDT
2003344
H&N: Oral cancer; SCCmTHPC
Phase IIb
0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−2114Eighty-five percent at year 1
Seventy seven percent at year 2
Mild-to-moderate skin photosensitivity for 13% of patients. Survival: 89% at year 1; 75% at year 22004334
H&N: “last hope salvage treatment”mTHPC
IPDT
0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW per fiber), 20 J cm−245Twenty percent complete response after 1 month + 53% symptomatic reliefOne carotoid blow out 2 weeks after PDT
Five patients’ disease free and alive 10–60 months after. Median survival: 16 months for 33 responders; 2 months for 12 nonresponders
2004353
H&N: SCC, patients unsuitable for other treatmentmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−2128Thirty-eight percent overall tumor response
Sixteen percent complete tumor response
Fifty-three percent of patients with significant clinical quality-of-life benefit2004341
H&N: Oral cancer: Nasopharyngal carcinomamTHPC
Phase I/II
λ = 652 nm14Effect of new light applicatorLarge interpatient variations2006348
H&N: Lymphatic and venous malformationsmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J per fiber11Better results with lymphatic malformationsSide effects: Pain and swelling2007347
H&N: Oral cavity and oropharynx neoplasm, SCCmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 653 nm (100 mW cm−2), 20 J cm−224
35
CR: 50% after 1 a
Partial response: 37.5%
Mean duration of overall survival: 305.7 ± 199.4 days
Mean duration of recurrence-free survival: 302.7 ± 144.9 days for patients with complete remission
Mean duration of overall survival: 401.43 ± 321.25 days
Mean duration of recurrence-free survival: 327.7 ± 131.1 days
2008
2009
342
343
H&N: And limbs, variousmTHPC
Evaluation of ultrasound-guided IPDT
0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−26814/17 improved breathing
25/30 improved swallowing
16/22 improved speech
33/40 reduction in disfigurement
IPDT good modality for treatment with deep-seated pathologies2009355
H&N: SCCmTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−239CR: 54%Median survival significantly longer for responders (37 months) than for nonresponders2010351
H&N: Cystic hygromamTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−21Five-month-old-male patient: IPDT, reduction in size of lesionCase report2010358
H&N: Oral cavity and oropharynx neoplasms (Tis-T2)mTHPC0.15 mg kg−1mTHPC, 4 days, λ = 652 nm (100 mW cm−2), 20 J cm−217090.7 overall response rate; CR 70.8%Detailed subgroup analysis identified oral tongue and floor of mouth sites as suitable subsites2011350
Lung: Recurrent respiratory papillomatosismTHPC
Phase I/II
0.15 mg kg−1mTHPC, 6 days, λ = 652 nm, 60–100 J cm−215Thirty-three percent in remission after 1 aRecurrence after 3–5 a
Tracheal disease was not responsive to PDT
2005437
Pancreas: Inoperable adenocarcinomamTHPC
Phase I
0.15 mg kg−1mTHPC, 3 days16Median survival time: 9.5 months
Forty-four percent patients alive after 1 a
Abdominal pain after procedure
Three patients developed duodenal obstruction perhaps related to treatment
2002/2003423
569
Pericarotid malignant diseasemTHPCEndoluminal carotid stenting prior to Foscan PDT; 0.15 mg kg−1mTHPC, 4 days, λ = 652 nm, 20 J cm−21Reduces carotid artery ruptures during the treatment of peri-carotid diseaseCase report2010359
Prostate: Recurrent prostate cancer after radiotherapymTHPC
Phase I
0.15 mg kg−1mTHPC, 3 days, λ = 652 nm, varying number of fibers14Thirty-six percent no tumor after 2 months
Necrosis in 91% of cross sections
Side effects: stress incontinence (four patients), significant impairment of sexual potency
No rectal complications
2002424
ProstatemTHPC
Phase I
0.15 mg kg−1mTHPC, 2–5 days, λ = 652 nm, 50 to 100 J per site6Prostate specific antigen fell up to 67% after 8/10 sessions 2006427
Skin: BCC and Bowen’s diseasemTHPC gelTopical application, λ = 652 nm (60 mW cm−2), 25–150 J cm−2, repeated treatments28Sixty-four perent response
Thirty-two percent pathological clearance
 1999364
Skin: BCCmTHPC0.1 mg kg−1mTHPC, four consecutive days, λ = 652 nm (100 mW cm−2), 5–15 J cm−25One hundred and eighty- seven tumors: 86% complete response after 18 months with 10/15 J cm−2 d1 or d2Edema and erythema around the treatment site more severe on day 1 than after longer intervals; good cosmetic outcome2001365
Skin: BCCmTHPCApplicationo of 5-FU cream (Efudix) for 3 weeks prior to PDT. 0.15 mg kg−1mTHPC, 3–4 consecutive days, λ = 645–655 nm (100 mW cm−2), 10–15 J cm−21Case report: Effect of 5-fluoro-2′-deoxyuridine and PDTSignficant side-effects: Edema, ulceration, redness; healing delayed by 2 months2003459
Skin: BCCmTHPC0.1 mg kg−1mTHPC, 0.5/1/2/3/4 days, λ = 652 nm (100 mW cm−2), 10 J cm−213Best results after 1 day when plasma level is high CR: 75% (274 of 366 lesions) after 6 monthsIncludes five patients from ref. 414
Good cosmetic results and tumor response was evaluated at 6 months and 1 year
Two cases of discolored veins at injection side after weeks to months
2006366
Skin: BCCmTHPC0.03–0.15 mg kg−1mTHPC, 1–96 h, λ = 652 nm, 20–120 J cm−2117Four hundred and sixty BCCs After 8 weeks: Overall CR: 96.7%
CR 100% with 0.05 mg kg−1mTHPC, 48 h, λ = 652 nm, 50 J cm−2
Very good cosmetic outcome
Side effects: Pain and phototoxicity
Severe sunburns with scarring in three cases
2008345
Skin: SCCmTHPC0.05 mg kg−1mTHPC, 2 days, λ = 652 nm1Optical coherence tomography tumor mapping prior to PDT; CR after 6 monthsCase report2011367

A first comprehensive meta-analysis of the available data on PDT for most applications has just been published by Fayter et al. (317). They analyzed 88 trials reported in 141 publications and clearly outlined the problems associated with the currently available data. Their analysis indicated good prospects for PDT for actinic keratosis and Bowen’s disease. Likewise PDT of BCC might be superior to surgery or cryotherapy due to better cosmetic outcomes. Similar indications for Barrett’s esophagus were promising but no conclusions could be made for esophageal cancer. Limited evidence was noted for applications in lung, brain and H&N cancer and cholangiocarcinoma. Overall, no significant adverse side-effects were noted. The authors noted as problematic the absence of large scale randomized control trials and noted limitations in the quality of life and resource outcome reporting.

Side effects

Obviously photosensitivity is a major concern for light-activated drugs. Several studies have indicated that mTHPC results in less photosensitivity than Photofrin (132). Still, the major problem involving mTHPC PDT is skin photosensitivity in the few weeks postdrug administration. Injuries resulting from this light hypersensitivity are generally minimized by following medical advice. Thus, burn-related incidents are rarely seen in PDT patients; those that are observed mostly occur when medical advice is ignored. However, in isolated cases, injuries have been received during treatment in the operating theater where devices such as the pulse oximeter have been a source of causing burns to the victim (318). To reduce the risk to patients several types of creams have been tested on patients and, for example, dark cover cream promises acceptable protection (319). Other side effects are mild to moderate pain in the treated area. More specific, but also rarer, are side effects related to specific cancer treatment protocols, e.g. for esophageal cancer (vide infra).

In 2000, a report of post PDT partial sickness burn occurring in 6 of 12 patients was challenged by the Foscan producers and created a lively debate in BMJ. As then no similar reports have been made and it appears to have been the result of the drug application procedure. The furor created by this report and its subsequent discussion in the scientific literature and (financial) mass media is an illuminating example for the interrelationship of financial interests, research, scientific publication ethics and news spin (319).

Head & neck

Foscan was first approved in 2001 in Europe for the treatment of advanced H&N cancer. There is a relatively high morbidity and cost associated with standard head and neck mucosal squamous cell cancer treatment. Typically, therapy involves a combination of radical surgery, radiotherapy and chemotherapy. Radiotherapy to the head and neck area commonly causes a wide range of debilitating side effects, such as xerostomia, mucositis, loss of taste and loss of smell (320). In severe cases, malignancies have sometimes been found unsuitable for any treatment because of the imminent loss of functionality. The treatment of squamous cell carcinoma (SCC) of the soft palate is an example (321); however, there are many more. While multidisciplinary H&N cancer care is well established (322), PDT has been slow to gain an entry (302). In an overview from 1997 on multitreatment approaches it was mentioned only as an emerging technique (323). More recent overviews of this area are available (324–326).

Nevertheless, while it was initially only used for palliation in inoperative patients with advanced stage H&N SCC, PDT quickly was used with a curative intent for the treatment of small localized and recurrent tumors and premalignant lesions. Initial clinical studies were promising and showed that PDT is suitable for the treatment of early (CIS, T1) carcinomas and of small T2/T3 superficial carcinomas (<0.5 cm) (327). Likewise, fluorescence guided resection was quickly shown to be a feasible option (328). In situ dosimetry during oral cavity illumination is indicated and should be required as the basis for light dose prescription in H&N PDT (329).

The introduction of mTHPC PDT, even as an adjuvant treatment, has offered a new possibility of tumor clearance and possesses the advantage over the related use of ALA or Photofrin, in that much lower drug and light doses are required (330,331). The length of time skin remains photosensitive is halved while deeper tissue penetration is achieved. The pharmacokinetics of mTHPC were studied by Braichotte et al. in early clinical tests on patients with SCC in the oral cavity using fluorescence spectroscopy and a noninvasive optical fiber (332) and later in a hamster model (240). The measurements were performed at 420 and 520 nm and showed encouraging results for oral SCC at both wavelengths. A more recent trial using standard conditions with longer mean follow-up times (37 months) of early SCC in the oral cavity resulted in a total clearance of 86%, which underlines the usefulness of mTHPC for these and similar cancers (333). The complete response rates for mTHPC PDT are similar to those of surgery and/or chemoradiotherapy but with the advantage of a lower morbidity and better cosmetic results (331,333,334).

The first studies on 17 H&N cancer patients (SCC, malignant melanoma and verrucous carcinoma) treated with different PS (15 Foscan, 1 ALA, 1 Photofrin) were published in 1995 and were encouraging (330). An early explicit trial including 20 cases of SCC and BCC confirmed the potential use of low light dose (5–10 J cm−2), and found the outcome of treatments at low light dose preferable as selectivity of necrosis of normal to cancer tissue was often higher (335). However, this only was found to be true for minor lesions. All cases of SCC showed complete response with a follow-up of 8–24 months. Lymph node metastasis was shown to be absent. Complete response of BCC was slightly lower (92%) with the remainder showing only partial reduction of the tumor. mTHPC-mediated PDT was found to be superior to that of Photofrin, ALA and BPD. Additional medication (e.g. antibiotics or pain reliever) after irradiation was unnecessary as side effects were minimal. Side effects only occurred because of oppositional behavior to medical advice (burns due to exposure to open daylight during the first weeks after treatment).

But do isolated tumors and “field change” tumors (multiple lesions at one anatomical site) respond equally well to irradiation? Clinical trials performed by Bown’s group on various oral SCC’s indicated that isolated lesions gave the best PDT response whilst cases of “field change” showed less photoreaction and often incomplete necrosis of cancer tissue (336). Repeated treatment at higher light doses sometimes led to an improved outcome. Still, evaluation of a variation of the light dose between 5 J cm−2 and the recommended 20 J cm−2 suggested that lower light doses might very well be sufficient for smaller isolated lesions.

In early 2001, the possibility of treating head and neck cancer with mTHPC PDT came to be known more broadly as two complete Phase II studies showed encouraging results (337,338). Kübler et al. examined 25 patients with primary lip SCC and showed a 96% complete response after 12 weeks (337). A brief report on the treatment of lip cancer was also published in 1995 (339) and followed by a case report indicating good cosmetic results (340). About this time, Scotia sought regulatory approval in the USA and Europe for palliative use of Temoporfin in head and neck malignancies. Extensive clinical research in a Phase III study had confirmed an improved quality-of-life benefit in 53% of patients with incurable cases of recurrent/refractory SCC of the head and neck (341). Other clinical studies have been reported as well and indicated good results with patients for whom all other treatment options had been exhausted (342,343).

The efficacy of mTHPC in the primary treatment of a wide range of head and neck mucosal SCC was reinforced in 2003 (344). Although this study encompassed a rather heterogenous group of patients with oral cavity, nasal, oropharyngeal, hypopharyngeal and laryngeal malignancies, some of which had already received radiotherapy, the results were promising. A CR to primary treatment was seen in 19 of 21 patients (90%) in tumors ranging in stage from T1 to T3. Treatment of laryngeal cancer, recurrent postradical radiotherapy, however, was less successful, with only 25% of patients showing CR. This study concluded that while the complete response rates are similar to those of surgery and chemoradiotherapy, PDT had a lower morbidity rate. There is also the ability to retreat or treat uncompromised areas with standard techniques in the event of a recurrence. Prime sites for PDT when treating head and neck mucosal SCC were established to superficial looking (around 5 mm depth) floor of mouth, buccal pouch, lip, lateral pharyngeal wall/tonsil, soft palate and posterior pharyngeal wall carcinomas. Larger studies of BCC skin cancer in the H&N region with Foscan indicated 97% CR after 8 weeks and a 100% CR with low doses of Foscan (345). Thus, H&N PDT appears to be one area where PDT significantly improved on other treatment approaches (346). Foscan has been used clinically for the treatment of benign neoplasms in the H&N as well. All cases showed a significant reduction in the volume of abnormal tissue; better results were observed with lymphatic malformations compared to venous ones (347). Other studies involved use of a new light applicator for nasopharyngal cancer (348,349).

A contemporary Dutch study analyzed the results of Foscan treatment of early stage oral cavity and oropharynx neoplasms in 170 patients with 226 lesions (350). The very promising results gave an overall response rate of 91% and a CR of 71%. However, clearly the selection of the patients is of critical importance for the outcome of the treatment. A thorough subgroup analysis revealed that some sites (e.g. oral tongue and floor of mouth) are more suited to PDT treatment than others (e.g. alveolar process, soft palate). Unfortunately, the latter are the areas that are less suited for conventional surgical resection. Nevertheless, the success rate is promising, side effects were acceptable and the PDT effect was independent of the T stage for invasion depths <5 mm. Overall, Foscan PDT appears to be a suitable first treatment for areas that would have functional problems after resection. A recent multicenter study of Foscan use for H&N SCC showed complete response in 19 of 39 treated patients with a significantly increased median survival (37 months compared to 7.4 months) (351). Mild-to-moderate side-effects were observed, the most significant ones related to photosensitivity, pain and dysphagia. Foscan was the first PS to be investigated for its utility in H&N cancer in a multicenter study (352).

A second way to raise the effectiveness of treatment of large tumor sites was the advent of IPDT (353). IPDT involves the penetration of the cancer tissue with the optical fibers during irradiation to insure complete irradiation of the malignancy (354). Utilizing this modality on some recurring head and neck cancers has delivered some impressive results. Several patients, previously regarded as otherwise unsuitable for any further treatment, showed a complete response (11% after 10–60 months) after mTHPC PDT. Nevertheless, in some cases repeated PDT was necessary to reach this outcome. A recent, larger study with 68 patients with various deep-seated pathologies showed that ultrasound-guided IPDT was well tolerated and that image-guided PDT gave improved results. Quality-of-life assessments were found to be a good criterion for the results, especially since the clinical results vary for patients with the same disease (355). Optical guidance methods for PDT in this area are currently under development. One study explored the use of fluorescence differential path length spectroscopy for monitoring Foscan IPDT (356).

Similarly, the use of surgical palliation using PDT is becoming more developed for the treatment of end-stage head and neck cancer. An excellent overview on the current best practice of this modality has been given by Jerjes et al. (357). A case study reported Foscan PDT use for the treatment of cystic hygroma in a 6-month-old-patient (358). They also presented a case study which showed that the occurrence of carotid artery rupture in the treatment of peri-carotid disease can be reduced via endoluminal carotid stenting prior to PDT (359). Other areas of potential use include the hyoid. Chrondrosarcoma of the hyoid has been reported to be radioresistant and cannot effectively be treated with chemotherapy, which typically leaves hyoidectomy as the only option, resulting in disruption of speech, swallowing and respiration. A case study showed that IPDT can be used effectively for this treatment (360).

Practical applications also demand a cost-effectiveness analysis. An analytical model was developed for the UK market using a computerized cost-effectiveness model. It revealed that palliative mTHPC PDT used against advanced head and neck cancers not only resulted in an increase of life quality avoiding the common side effects of extensive palliative surgery or palliative chemotherapy but was also much more cost-effective than the other optional treatments or even nontreatment (361). This study also showed significant health gains. Of the three treatment strategies PDT gave 129 extra days of life compared with no treatment and extensive palliative surgery and 48 extra days of life compared to four cycles of palliative chemotherapy. This model was also used for Germany using the local cost data in 2005 and confirmed the results of the British study. Financial costs for PDT were 8761€ compared to 11 600 for four cycles of palliative chemotherapy (362).

Skin

Due to the accessibility by light skin cancer is a natural target for all PDT drugs (304). For a comprehensive clinical review on cutaneous malignancies see Allison et al. (363). Several in vitro and animal studies (249) were performed and established the principal effects of Temoporfin in this area. A pilot study using a gel formulation of mTHPC for topical treatment of BCC and Bowen’s disease showed some response but was found to be inferior to both intravenous mTHPC PDT and topical PDT with ALA (364). Still, initial studies of the treatment of BCC (304) were promising with about 86% complete response (365). A slightly larger study optimized the drug-light interval and showed that light activation after 1 day gave the best results with 75% CR after 6 months (366). Even better results were observed in a larger study with 117 patients where an overall CR of 96.7% was reported (345). Overall, the clinical and cosmetic results are promising. Foscan has also been used in a case study to evaluate the utility of optical coherence tomography-guided PDT. Administration of a 0.05 mg kg−1 dose 2 days prior to tumor mapping followed by light treatment of the mapped area resulted in CR at 6 months (367). A recent review has addressed clinical treatment decisions for topical PDT in nonmelanoma skin cancers (368).

GI tract—esophagus and bronchi

The esophagus is often the site of second primary tumors occurring in patients suffering from SCC in the head and neck. PDT quickly became of interest for the relevant clinicians due to the possibility of endoscopic light delivery (305–308,369). Nevertheless, only a few groups were the driving force behind this obvious application in the early years (370). As mTHPC PDT already showed success in these areas, and as esophageal cancer had previously been treated with Photofrin® PDT, it was logical to test the effect of mTHPC PDT on esophageal SCC (371) or Barrett’s esophagus (372). Preliminary studies (370) on the impact of treatment on patients with (second) primary SCC located in the esophagus or the bronchi showed success (373) and were confirmed in subsequent studies (374,375). For example, a total clearing rate of 84% in the treatment of early SCC in esophagus and bronchi was found after a mean follow-up of 15.3 months (376). With the assistance of fluorescence spectroscopy, an adjustment of the fluence rate to only 8–12 or 7–16 J cm−2, respectively, was possible. An analysis of the early studies in this area using various PS in the GI and aerodigestive tract was given by Radu et al. (371,374) and they discussed their experiences with PDT and endoscopic mucosal resection in Switzerland in detail (275).

Experiments performed by Braichotte et al. on oral SCC were extended into other treatment sites in patients such as the esophagus (377) and bronchi (378). The results showed that while there was a direct correlation of photosensitizer accumulation (as detected by fluorescence spectroscopy) to PDT response in the tumor, the efficacy between patients varied largely. This is largely due to each patient having an individual pharmacokinetic response and rate of metabolism for the same drug-time level. Thus, the efficacy of PDT in the esophageal and bronchial SCC can be improved by prior monitoring of the accumulation of mTHPC in the tumor cells and before applying the correct light dosage. Zellweger et al. demonstrated that this is indeed possible in a study with five patients and avoids to a certain extent over- or underirradiation, hence increasing total response rate and abating side effects (379). However, due to the difficulty of endoscopic measurements, fluorescence measurement of the oral cavity was recommended as the ideal methodology. Indeed, it was shown that intrapatient fluctuations in oral measurements were two to three times smaller than in endoscopic procedures, thus being more reliable.

Light dosimetry is especially important in esophageal treatments (380). To facilitate endoscopic irradiation in esophageal PDT, a through-the-scope balloon applicator was proposed and tested on a small number of patients who underwent either mTHPC or ALA PDT (381). In the bronchi, the complex and elaborate architecture of the tracheobronchial tree leads to less accurate delivery. Consequently, the risk of recurrences due to probable undertreatment is enhanced for this site. But at least in early noninvasive tumors slight overillumination might help, as nonmalign bronchial cartilage has a low uptake of mTHPC and is hence relatively insensitive to photosensitization. But still, sufficient light delivery in this part is a medical challenge.

Although early esophageal SCC was found to respond very well to mTHPC PDT, irradiation at 652 nm also led to necrosis of a substantial amount of surrounding normal tissue and a deeper level so as to impair functionality. This often led to heavy side effects due to perforations and the development of tracheo-esophageal fistula. To avoid this, therapy with green light (514 nm) was introduced, allowing light penetration of only a few millimeters which subsequently diminished the undesired photosensitization of deeper tissues (382, see also 377). As one means of optimizing PDT for this particularly sensitive area, Blant et al. studied the time-dependent histological localization in the aerodigestive tract by comparative fluorescence spectroscopy of normal and malign tissues (383). However, for advanced invasive tumors in the esophagus it is likely that, due to the mentioned disadvantages, conservative treatment (surgery, radiotherapy) is the better choice at present.

Recent studies have shown success with mTHPC PDT in patients with Barrett’s esophagus (384,385) and/or adenocarcinoma (386). Both conditions are closely related to one another as patients who show a Barrett’s associated dysplasia are 40–50 times more likely to develop an adenocarcinoma than the general population. Thus far, PDT is only used for high-grade dysplasia or carcinoma. The initial results suggested that response rates with mTHPC PDT are better compared to ALA or Photofrin, with a 100% clearance rate of early stage neoplastic lesions and a complete re-epithelization of the squamous within a mean of 34 months using green light. Interestingly though, a comparative study was performed by Lovat et al. recently in the treatment of dysplasia and early esophageal cancer using red and green light (387). In this study, the most effective light-delivery technique was found to be the use of red light equipped with a diffuser. Note that this study pointed out that complications (including death) can arise from taking biopsy species too early. It was recommended that biopsy specimens should not be taken for at least 2 months after treatment. A comparative analysis of the various PS available in 2004 concluded that depending on the presence or absence of macroscopic abnormalities Photofrin or ALA might be the best indication (388).

As adenocarcinoma is a very severe illness with a 1-year-survival rate of only around 20% the different light-delivery techniques recommended in the various studies complicate the issue of treating esophageal cancer using PDT. As a result, the general conservative solution remains esophasectomies as the primary solution. Despite this, mTHPC PDT offers a potential second line treatment and a solution for patients who are deemed inadequate for surgery. For a recent review of this rapidly developing field see Gross and Wolfsen (389).

Chest

The very first published clinical work with mTHPC described trials investigating the photodynamic effect in the treatment of diffuse malignant pleural mesothelioma, an asbestos-related cancer (390). This severe disease is characterized by its resistance to conventional modalities such as surgery, radiotherapy and chemotherapy (391). Even with radical resection combined with chemoradiotherapy, close to one third of all patients develop a recurrence of the malignancy and a small number develop multiple recurrences (392). The tumor is fast growing and very aggressive in invading the surrounding vital structures and thus only cases in which early detection is achieved are classified as suitable for surgery. In these instances two procedures have been established depending upon the severity of the malignancy: extrapleural pneumonectomy, which involves the radical removal of one lung or pleurectomy, a procedure involving the debulking of the tumor. Extrapleural pneumonectomy is accompanied by heavy morbidity. While pleurectomies are less morbid for the patients there is an associated enhanced risk that the original tumor tissues remain in the chest cavity. The main drawback to both surgical procedures is that mesothelioma has the tendency for frequent local recurrence within a short time with associated high lethality. A recent review on the use of PDT in this area was given by Lindenmann et al. (393) while a comparison of the state-of-the-art techniques was published by Yarmus et al. (394).

At present cryotherapy, brachytherapy and PDT are the three methods suitable for the endoluminal treatment of lung cancers. While no comparative studies have been published it appears as if a complementary use of these methods is indicated. Cryotherapy is cheap and is suitable for the treatment of superficial tumors (3 mm) similar to PDT, while brachytherapy allows a deeper invasion into the bronchial wall and thus allows the treatment of more aggressive tumors (395). As mTHPC PDT was known to be superficially effective against certain malignancies Ris et al. tried to combine mTHPC PDT with the known surgical procedures (390). The idea was to illuminate the tumor surrounding surfaces in the regarded chest hemisphere posttumor removal to destroy remnants of malignant tissue, thus improving local tumor control. Investigations of the potential conditions for PDT on mesothelioma were carried out with some preliminary experiments using nude mice bearing human malignant mesothelioma xenografts (148,149). These studies also showed the utility of pegylated mTHPC (257) and the importance of the drug-light interval. Likewise, low oxygenation levels either resulting from oxygen consumption or vascular occlusion may adversely affect the PDT effect (396). This can be counteracted by nicotinamide injection and carbogen breathing (259).

In a first Phase I study on diffuse malignant mesothelioma of the chest, Ris et al. concluded that 0.3 mg kg−1 drug dose should be combined with a total fluence of 10 J cm−2 at a drug-light interval of 48 h. The study used surgical tumor resection followed by IOPDT with mTHPC. These conditions led to tumor necrosis of up to 10 mm in depth (397). Such a high impact at such low light dose had not been reported with either HpD or Photofrin previously and was an early indication for the utility of mTHPC in PDT. However, the treatment of more patients with longer follow-up times revealed that the chosen conditions were less than optimal. Longer drug-light intervals (72 h) showed a greater selectivity for tumor necrosis and less pronounced burning of normal tissue.

IOPDT was initially faced with a number of difficulties. First of all, the equal illumination of the surface of the lungs takes a very long time, increasing operational theater times which made the already heavy impact of the procedure on the patient even more troublesome (398). The fact that the large areas to be treated were complex and delicate did not help to make the practical work and estimation of the correct fluence any easier on the physician. Due to the therapy taking place in the chest, the vicinity of the site being treated also houses many of the vital organs, thus overillumination must be avoided. As a direct result of IOPDT, patients showed an additional morbidity beyond that of surgery alone, but the procedure related mortality rate was thought to be comparable to surgery without the adjuvant phototherapy. In a follow-up of 4–18 months, all patients developed either contralateral disease or distant metastasis and eventually died of their illness. Thus mTHPC IOPDT of mesothelioma has so far not led to improved survival rates, but has given some conditions for better local tumor control if the pathways for cellular localization for this type of cancer can be understood better. Further PDT developments in this area will depend on improved sensitizer accumulation and a more detailed understanding of the synergistic effects between PDT and chemotherapeutic agents.

Several other clinical studies were performed in this area (399,400). In a preliminary study, Baas et al. introduced a light-delivery system that allowed integral chest illumination and reduced the treatment time significantly. After patients had undergone extrapleural pneumonectomy the cavity was filled with a sterile plastic bag with 2.5–4 L saline solution. The bag contained a spherical bulb fiber as light source. Four isotropic detectors were positioned at various places within the chest cavity therefore allowing real-time light dosimetry. The fiber was repositioned in a way that all detectors reported comparable fluence rates. During a succeeding Phase I/II study adjustments to the conditions were made for adjuvant PDT alongside EPP to 0.1 mg kg−1, 10 J cm−2 and 96 h drug-light interval, as previous treatments with 0.15 mg kg−1 led to several fatalities (401). However, the choice of quantities and light dosage for IOPDT was difficult due to the small number of patients in the study (28 in this particular case). Twenty patients showed local or distant recurrences during follow-up; however, local control could be registered in about 50% of the patients. A median follow-up of 31 months showed a median survival time of 10 months.

Friedberg et al. recently carried out a Phase I study combining surgical debulking (either by pleurectomy or extrapleural pneumonectomy) and adjuvant mTHPC mediated PDT (400). The maximally tolerated dose of mTHPC PDT was found to be 0.1 mg kg−1 with a fluence rate of 10 J cm−2 after a 6 day drug-light interval. Patients treated at higher doses showed several cases of acute capillary leak syndrome, which was assumed to be a dose-limiting toxicity; the PDT treatment correlated with an increase in interleukin-6 level (402). It was concluded that, unlike most other surgery-based multimodal treatments for mesothelioma, mTHPC PDT affords the option of accomplishing tumor debulking with a lung-sparing procedure rather than an extrapleural pneumonectomy. IOPDT has so far not been an answer to the highly metastatic nature of the disease (occurrence in >50% of all patients) but in future optimized IOPDT-gained local tumor control might become part of a combined treatment strategy. Note, that the 6 day interval differs from the standard 4 days used by Schouwink et al. (401). Both studies taken together clearly indicate that compromises between minimizing toxicity, maximizing efficacy and ability of the patient to tolerate the procedures will always need to be made on a case by case basis (403,404). An excellent review of the practical aspects of clinical use of PDT and IOPDT for malignant pleural mesothelioma has been given by Friedberg (391). A few meta-analyses have addressed the use of PDT for malignant pleural mesothelioma in general. Moghissi and Dixon compared data from 10 papers (up to 2004) with 230 patients (170 with Photofrin, 60 with Foscan) (405). They calculated an overall mortality of 4.9% for Photofrin and 13.3% for Foscan. Morbidity was 38% and 70%, respectively. Overall, the mortality and morbidity associated with IOPDT was not larger than that of the related surgical procedures.

Breast cancer offers another possible area for PDT (312,406). This was indicated by early in vitro tests (217). Breast cancer patients with chest wall recurrences after mastectomy were treated successfully with mTHPC. In a study by Wyss et al. all 89 treated lesions showed complete responses (407). Two different conditions of treatment (0.1 mg kg−1, 5 J cm−2, 48 h or 0.15 mg kg−1, 10 J cm−2, 96 h) led to comparable results. The amount of pain during the first days after treatment differed considerably, depending on the size of illuminated area, but was controllable with analgesics. Still, normal tissue morbidity was relatively high.

Gynecological malignancies

For general reviews on the use and utility of PDT in this area see Gannon and Brown (408), Allison et al. (299) and Hillemanns et al. (316). Relevant in vitro and ex vivo tests have been described above (231). The use of mTHPC in gynecological cancers was initiated by Wierrani et al., who reported success in a small group of women suffering from recurrent intraperitoneal carcinoma of the ovary (409). Postoperative observations showed total clearance and a significant improvement of life quality. A study of eight patients with terminal disease and treated with IOPDT also indicated the utility of this drug (410). Continued work on recurrent ovary, cervix and corpus cancers showed responses in selected cases, but whether a significant life extension can be achieved remains unclear as the number of reported patients up to now is limited (411). Other investigators treated four advanced cases of SCC or adenocarcinoma located in the vulva, vagina or cervix with a rather unsuccessful outcome. The overall survival of the patient was between 3 and 4 months (412). In these instances, the patient suffered local recurrences despite an initial good PDT response, or developed systemic disease. One explanation offered was the advanced status of the tumor being beyond recovery.

mTHPC PDT was also found to be an effective measure in the treatment of vulval intraepithelial neoplasia (413). Most of the patients exhibited total response with a follow-up of 2 years. Subsequent management, like minor excisions or multiple sessions of PDT, was required in most cases. However, good cosmetic healing and preservation of function was reported overall. A case study of vulval intraepithelial neoplasia III (severe atypia) with a lowered drug dose (0.05 mg kg−1) gave excellent results in a case study (414). For a recent review on PDT of human papillomavirus-related genital dysplasias see Soergel and Hillemanns (415).

Other clinical uses

Naturally many other potential applications exist. These include the treatment of brain (309,416,414), prostate (9,310), pancreas (311) and others.

Brain.  Malignant brain tumors carry a lethal prognosis with a median survival of 15 months, despite surgery, radiotherapy and chemotherapy. As it is difficult to differentiate between glioma brain tumor tissue and normal brain tissue by examination, intraoperative fluorescence diagnosis has become an important tool for neurological cancer surgery. Most work in this field was done with the ALA/PpIX and HpD systems, which afforded promising results due to the articulated concentration differences between malign and normal tissue (416,417). Temoporfin has been tested for this purpose as well. An accordant procedure has been introduced and initial encouraging experiences on patients have been made using a combination of IOPDT and fluorescence guided resection. The results showed a limited advantage compared to the first-generation PS (418). One of the first larger studies was performed by Zimmerman et al. who conducted their experiments on 138 samples from 22 patients and were able to achieve 88% selectivity and 96% specificity from IOPDT involving fluorescence guiding resection of brain tumors such as glioblastoma multiforme (338). Similar selectivities and specifities were observed in other studies. For example, intraoperative photodiagnosis and fluorescence guided resection for radical tumor removal in a group of 25 patients improved the tumor prediction and gave a radical resection in 75% under fluorescence guided resection compared to 52% in the control group. The median survival time for the PDD/PDT group was 9 months compared to 3.5 months in the control group (419).

Stomach.  A preliminary study of mTHPC PDT of early cancers of the stomach resulted in 80% total response in cancers of the intestinal type at a mean follow-up of 12 months (420,421). The drug dose chosen was lower than usual (0.75 mg kg−1) to obviate possible perforations. It was concluded that if this encouraging outcome was to be verified in following studies with larger numbers of patients mTHPC PDT could become a therapeutic option alternative to radical gastrectomy (421).

Pancreas.  An initial study of normal hamsters indicated that the normal pancreas is able to tolerate PDT well, indicating that PDT might be a good modality for treatment of pancreatic cancers (272,422). This was confirmed by a related transplanted pancreatic cancer model (274). In 2002, two Phase I studies were reported on the application of percutaneously implemented mTHPC on inoperable adenocarcinomas localized in the pancreas (423) and on locally recurring prostate cancer (424). Several needles were inserted into the tumor separated by ca 1.5 cm to deliver light in both of these circumstances. Optical fibers matching these needles were subsequently inserted. During illumination, the needles were pulled back step-wise in ca 1 cm steps to cover the entire tumor with the same light dose. For the pancreatic cancer, substantial tumor necrosis was reported. The median survival rate was an encouraging 9.5 months and the quality of life was found to be improved after PDT in most patients. Recurrences at the site of PDT were not found, but often occurred at the periphery indicating that illumination should include more tumor surrounding tissue. However, the use of PDT was complicated if either major blood vessels or the duodenum wall were involved with the tumor. PDT on tumors located at these sites led to notable bleeding or perforation of the duodenum after PDT. The prostate adenocarcinomas showed significant tumor response but PDT was commonly accompanied by loss of sexual function and discomfort in urination. Still, conservative treatments of this disease have similar or worse side effects and thus further research in this is warranted (311). Later in vivo studies with a hamster model showed that Verteporfin gave a profile similar to Foscan, however with the added benefit of shorter drug-light intervals and elimination times (425).

Prostate.  A recent clinical review was given by Ahmed et al. (314) and a comparison of the state-of-the-art use of lithotripsy versus PDT was published by Waidelich (426). mTHPC was first used in studies with dogs and was shown that it can be safely used for treatment of the gland (285). Next PDT was described as a salvage treatment after failure of external beam radiotherapy (424). A Phase I study showed that prostate cancer can indeed be treated; the level of prostate specific antigen fell by up to 67% in the six patients tested (427). Dosimetry is of critical importance for an effective treatment in this area (428). In this context an interactive dosimetry by sequential evaluation module has been developed for clinical trials of primary prostate cancer with Foscan (429). Preliminary studies on the use of IPDT have been reported as well (430). Alternative minimally invasive techniques are cryotherapy and high intensity focused ultrasound.

Biliary system.  PDT treatment of bile cancers is only slowly emerging (431,432). A significant problem for the palliation of patients with malignant bile duct obstruction using metal or plastic biliary stents is stent occlusion. In this context endoscopically performed Foscan PDT was investigated in 13 patients with malignant biliary carcinoma obstructions (nine biliary tract, three pancreas, one stomach). All patients had been initially palliated with stents; however, recurrent obstructive jaundice had occurred due to local tumor progression. After PDT tumor necrosis and/or metal stent recanalization was observed in all patients and the median patency of plastics stents increased from 3.5 to 5 m. Median survival times increased from 8 to 21 m. However, although PDT was tolerated well, significant complications were observed in this study (433). At present intraoperative radiotherapy appears to be more suitable. However, preliminary data of PDT in bile duct cancer gave good reduction of cholestasis, improvement of life quality and prolongation of survival time (434,435). Studies on cholangiocarcinoma are presently expanding (233,436).

Papillomatosis.  Only one investigation has explored the efficacy of mTHPC PDT in the treatment of recurrent respiratory papillomatosis (437). A reduction of the severity of laryngeal papillomas was seen during the first year after PDT. However, this was attributed to a probable improved immune response.

Retinoblastoma.  An initial study with Foscan utilized three xenograft cell lines derived from surgical samples taken from children. A significant response upon Foscan treatment was observed for one of the cell lines (RB111-MIL) and partial regression was observed after 60 days (438).

Anal cancer.  One study with four patients studied the use of a light applicator for the treatment of anal intraepithelial neoplasia Grade III. Here an applicator based on a standard anoscopy instrument was used and it was shown that blood saturation, volume and fluorescence and fluence rate can be monitored without changes in the light protocol (439). Nevertheless, a study with Fosgel administered to nine patients (eight HIV-positive males and two HIV-negative women) with anal intraepithelial neoplasia (III) showed no effect of the PDT treatment (440). This was attributed to the limited penetration of the liposomal formulation and the study of other topical PS applications is indicated.

Other applications

Many possibilities exist to use PS in areas other than cancer treatment. These include the well known treatment of age-related macular degeneration, use in dermatology (441), esthetics (photodynamic photorejuvenation), periodontal uses (442) and more. Sterilization and antibacterial action are clearly suitable application areas as well (443). Antifungal PDT may also be used, but has not been used with mTHPC derivatives yet (444). However, porphyrins, ALA and phthalocyanines have all been shown to kill yeast and dermatocytes through photodynamic action, indicating the utility of this approach. Use of mTHPC is ever expanding and will see many new applications in the near future. To give only one example, an interesting study by Hansch et al. showed that mTHPC-based phototreatment may be used for the treatment of rheumatoid arthritis (445). They used a murine antigen-induced arthritis model and found that mTHPC-PEG was taken up best in arthritic joints. Light treatment resulted in lowered arthritic scores at lower drug doses compared to what is used in cancer PDT. Thus, local treatment of arthritis appears to be feasible.

Ophthalmology

Ophthalmological applications for Foscan PDT are only slowly emerging (446). Liposomal formulations of BpD-MA and Foscan were tested in the chick chorioallantoic membrane model with regard to the treatment of choroidal neovascularization which is secondary to age-related macular degeneration. Here, PDT treated areas were treated with a soluble antivascular endothelial growth factor (recombinant human soluble VEGF R1 [sFlt-1]/Fc chimera). The topical application of this factor helped with occlusion and limited subsequent angiogenesis in a dose-dependent manner (447).

Antibacterial PDT

More and more studies with PS address their use for antibacterial action, including intracellular pathogens (325,443). A study from 1995 using isomers of THPP already indicated the potential antibacterial action of this type of compound (448). An early study into the antibacterial action showed that Foscan has antibacterial effects on Staphylococcus aureus (wild type) in the dark while hematoporphyrin derivative showed suppressive growth effects only after white-light illumination (411). Many of the newer derivatives and formulations of Temoporfin (vide infra) are now tested for the treatment of infectious diseases.

Antibacterial nanoparticle formulations are especially interesting. For example, a test of different cationic liposomal formulations of Foscan for antibacterial action showed that subtle variations significantly affect the uptake. Only one of the formulations tested gave results similar to the free drug (449). Likewise, calcium phosphate nanoparticles were surface-functionalized with different polymers, and PS was incorporated into this layer (450). Here, methylene blue and mTHPP showed good performance with HIG-82 synoviocytes. Moderate activity was found with HT29 epithelial cells while good photoxicity was found against S. aureus, both with positively and negatively charged nanoparticles loaded with mTHPP. The Gram-negative Pseudomonas aeruginosa could only be treated with positively charged nanoparticles containing mTHPP (451).

The dental care field has also become interested in PDT. Mostly this involves antibacterial PDT for periodontal applications (442). Such an approach is warranted as there is increased antibiotic resistance, the number of immune-suppressed patients has risen, and diverse pathogens play a role in periodontal infections, mandating different drug approaches. Foscan fluorescence in the buccal mucosa can be used to determine its concentration (379). A recent study investigated the effect of PDT on cariogenic bacteria. A comparative analysis of mTHPC and hypericin with Streptococcus mutans and S. sobrinus showed that the latter could easily be killed with both PS (the light source used was a dental polymerization instrument). At similar concentrations the former exhibited dark toxicity to mTHPC and no effect with hypericin. However, coadministration of both PS eradicated the bacterium effectively. Thus potentially there is a role for PDT in oral cavity antibacterial action. However, while the study showed very good results for a single bacterial species it appears that the really multispecies environment of the oral cavity presents a significant treatment problem (452). The use of Fospeg was studied as well. It provides a means to deliver an aqueous solution via spray techniques, and gave a significant reduction in bacterial cell count (453).

PDT combined with other methods

Naturally PDT is often used in conjunction with surgical treatments. However, some potential exists for the combined use with other cancer treatment protocols. This is a rapidly emerging field and includes the combined use of PDT with other chemotherapeutic drugs or immunostimulants and dual modality treatments.

PDT and chemotherapeutics.  Foscan PDT could be improved by coadministration of mitomycin C in an animal model (202). This allowed the use of lower light and PS doses for the same therapeutic effect. This effect did not occur when using a bacteriochlorophyll a analog. A water-soluble vitamin E analog, Trolox, has been shown to enhance the PDT effect. When administered together with the PDT drug it resulted in an increase in the tumor doubling time in a human tumor xenograft model (454). Possibly, this is the result of the Trolox-mediated radical pathway acting in conjunction with the singlet oxygen reactions; Trolox did not prevent photobleaching of the PS.

Immunostimulants have been shown to enhance the PDT effect in animal models (210). Adoptive immunotherapy using a human NK cell line (NK92MI) that was genetically altered to produce interleukin-2 has also been successfully applied to several human and murine cancer cell lines (455). BCG immunotherapy was found to be effective in a mouse mammary carcinoma model (256). Another possibility would be to impair the complement system to affect the antitumor response to PDT. Using mouse tumor models it was shown that for example Zymosan, an alternative complement pathway activator reduces the recurrence rate of tumors and increases the permanent cure rate (456). Likewise systemic complement activation with streptokinase and PDT treatment gave better results. Thus, complement activating agents can be used for adjuvant treatment. Another immunostimulant which has shown potential as an adjuvant for PDT is a glycated chitosan, described by Chen et al. (457). In a related study the ceramide analog LCL29 was coadministered with Foscan PDT and resulted in enhanced long-term tumor cure (458). The effect was highly specific for certain sphingolipids and indicated that the sphingolipid profile distribution can serve as a biomarker for the PDT response.

Clearly the combined use of chemotherapy and PDT would be attractive. However, early studies gave mixed results. In vitro tests of the effect of fluoropyrimidines with PDT showed a significant dependence of the outcome on the treatment protocol and the cell lines (MCF-7 and LNCaP) (459). A human case study showed significant side-effects and indicated the necessity for further studies (459). A validation of viability assays with two rodent tumor lines showed an increased PDT effect in the presence of the cytostatic drug doxorubicin (460). Similar results were obtained with studies on murine hepatoma (461). Interestingly, preliminary data indicate that the treatment of PDT + doxorubicin was better than first giving doxorubicin and then PDT. Thus, administration of doxorubicin directly after light treatment appears to be best (461). On the other hand, a study of murine leukemia treated with a combination of Foscan and either cisplatin or navelbine as chemotherapeutics and administration of immuno lymphocytes from PDT pretreated cells showed a significant synergistic effect (462). A possible means to lower the PDT effects on healthy tissues was reported from a pig stomach study. Standard Foscan PDT gave 71.4% full-thickness necrosis. However, with octreotide the PDT effect was only 28.5% (463). Octreotide is a somatostatin analog and decreases the splanchnic blood flow and has multiple inhibitory effects on the peptic system. Thus, it might be possible to down regulate the PDT effect in normal gastric tissue in pigs.

Dual treatment modalities.  A combination of PDT with other treatment modalities is indicated for several cancer types and has been discussed above. Typically this involves PDT in conjunction with surgery, chemotherapy or radiotherapy. For example, an early in vitro study of breast cancer cells already showed that PDT and radiotherapy effects are additive and independent of each other (234). Another possibility is the use of magnetic nanoparticles. This allows the combination of PDT with magnetic hypothermia therapy (464).

Nonmedical applications

The physical properties of mTHPC, although principally investigated for its potential as a PDT photosensitizer, have fortuitously resulted in its use in other applications. For example, mTHPC has been tested successfully as matrix material for the use in MALDI-TOF MS for low molecular weight compounds (47). Potential for application in a nonclinical area exists in the nutrition industry, where sterilization of surfaces is an important subject. The usefulness of non mTHPC PS was successfully demonstrated to kill microorganisms fixed on solid surfaces (465). Water sterilization is another potential application for PDT. In the context of the topic of this review one example is the use of immobilized 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin for the disinfection of water (466). This indicates that in practical terms PS which failed in medical terms due to high toxicity may still be useful for technical applications.

Related sensitizers and developments

Clearly, mTHPC has proven to be a successful and interesting photosensitizer to date. Thus, it is none too surprising that the development of new PS is partly resting upon the so far gained knowledge of its properties. In fact, a significant area of photosensitizer development relates to the modification of mTHPC in an attempt to address some of its shortfalls. This is similar to the situation for any other second-generation PS, where continuously advances are made with regard to chemical modification, different formulations or new targeting strategies. Many of these advances are related to new strategies for drug delivery (108). In addition, many PS drugs closely related to mTHPC are now available. For reasons of space only the developments relating to direct use of the mTHPC molecule will be described. An analysis of chemically related compounds will be given elsewhere. No real QSAR study involving the various derivatives has been performed for the latter and an assessment of their utility and benefits relies on individual studies and comparisons. Likewise, it is somewhat surprising that the p-isomer of THPP still often features in preclinical studies.

PEG Conjugates

General.  Efforts to modify the basic mTHPC properties through chemical manipulations began early in the Foscan “story.” In an attempt to improve the localization of mTHPC in tumor cells and its solubility, it was proposed that the construction of a photosensitizer-polymer conjugate would lead to an increased selective retention of the drug in tumor tissue resulting in an enhancement of selective tumor destruction by light in PDT (467). Since then the development and use of mTHPC-PEG (7) has developed almost into a separate research interest (223,251,252,256,280,291,468–482). In chemical terms pegylation of Foscan is achieved through etherification reactions of the hydroxy groups. Depending on the exact type of side chain attached (mostly its length) or the type of linker group used for attachment different types of mTHPC-PEG have been prepared. Examples are mTHPC-MD2000 (sometimes listed as SC102), mTHPC-MD5000 and others. Often the tradename Fospeg® is used as well. Sometimes clinical publications are problematic in that the exact type of “PEG” is not specified.

  • image(3)

[  Chemical formula of pegylated mTHPC. ]

Different materials require different detection methods. For the analytical detection of mTHPC-PEG, HPLC is not sensitive enough and spectrofluorimetric methods are better suited (468). MS analysis requires HPLC ESI-MS to separate the oligomers for molecular mass analysis (483). Its absorption spectrum is similar to that of unmodified mTHPC and the major difference in solution is the absence of dye aggregation effects. Based on the fluorescence quantum yield of chlorophyll a and mTHPC (0.22), mTHPC-PEG exhibited a slightly lower quantum yield of 0.19 in aerated ethanol (470).

Cell and animal tests.  Fospeg and analogs have tested in various in vitro and in vivo settings (Tables 2 and 3). Selected in vitro tests are compiled in Table 4. Representative cell studies included investigations on malignant mesothelioma (223,257,475,482). Chinese hamster lung fibroblasts (223), human colorectal carcinoma cells (470) and xenografts (467) and murine leukemic cells L1210 (470). Other examples were studies on ovarian cancer cells (474) with very high tumor/tissue ratios (280) and liver tumor models (478), which showed no significant advantage. For example, mTHPC-MD2000 in a rat colon adenocarcinoma resulted in an increase of PS concentration in the liver with time, thus resulting in a loss of tumor selectivity (478). In human prostate cancer cells Fospeg exhibited a lower LD50 than Foscan (484). In vitro studies related to ophthalmology were reported as well (447).

Table 4.   Selected cell lines used for in vitro studies with derivatives and formulations of mTHPC and related compounds.
Cell lineStudyCommentsYear    Ref.
Canine kidney cell; MDCK IImTHPP; bystander effectLower bystander effect compared to Photofrin2001  193
Hamster, Chinese; lung fibroblasts V79Test of phototoxicity and comparison with mTHPC-MD2000mTHPC-MD2000 has 100 times less dark toxicity and is 10 times less cytotoxic1997  223
Human bile duct cancer cells; BDCComparison Foscan and FoslipHigh potency for both, easier application with Foslip2007  232
Human breast carcinoma; MCF-7Test of phototoxicity and comparison with mTHPC-MD2000mTHPC-MD2000 has 100 times less dark toxicity and is 10 times less cytotoxic1997  223
Human cervix carcinoma; NHIK 3025mTHPP: Effect on mitosisMore effect with AlPCS41992   39
Human colon adenocarcinoma; Colo 206Test of liposomal formulationsMixing of DMPC and gemini surfactants2005  499
Human colon adenocarcinoma; HT29mTHPC-MD: PharmacokineticsMaximum fluorescence after 5 h1997  470
Human colon adenocarcinoma; HT29mTHPC encapsulated in nanocarriers:Reduced uptake but only small effect on phototoxicity and more localized pattern in cells2000  488
Human colon adenocarcinoma; HT29mTHPC invasosomesSimilar cytotoxicity for free mTHPC and delivered in invasosomes2010  519
Human colon adenocarcinoma; HT29Micellar formulation of mTHPCLess phototoxic than free mTHPC2010  532
Human colon adenocarcinoma; HT29pH sensitive PEGMA-co-DPA mTHPC nanoparticlesFaster release at pH 52010  534
Human colon adenocarcinoma; HT29Calcium phosphate nanoparticles with mTHPCNo effect2010  540
Human epidermoid cells, A431mTHPC invasosomesHigher cytotoxicity for mTHPC delivered in invasosomes compared to free mTHPC2010  519
Human epidermoid cells, A431Comparison of various PSFoscan and Fospeg lowest LD50, Photofrin lowest IC502010  539
Human gall bladder cells; GBCComparison Foscan and FoslipHigh potency for both, easier application with Foslip2007  232
Human glioblastoma; DBTRG, LN229, U118mTHPC liposomal formulationsCationic liposomes increase uptake2007509,510
Human glioblastoma; LN229,mTHPC liposomal formulation with Gemini surfactantsStereochemistry of gemini spacer affects drug uptake efficiency2010  570
Human H&N; SCC 14CmTHPC in micelles: Photocytotoxicity and uptakeHigh loading capacity (30%), uptake and PDT effect only in presence of lipases2008  531
Human H&N; SCC, HSC-3mTHPP in PEG-PLA micelles 2010  533
Human HeLa cervix cancer cellsComparison Foscan and Foslip, uptakeFluorescence lifetime measurements indicate initial aggregation2008  103
Human acute T-cell leukemia: Jurkat Jurkat cells (clone E 6-1)HSA nanoparticles with mTHPP, mTHPCNanoparticles more phototoxic than free drugs2011  526
Human esophageal cancer; KYSE 510mTHPC entrapped in silica nanoparticlesFifty percent lower cellular uptake than standard mTHPC
Drug is rapidly transferred from nanoparticles to serum proteins and then internalized by the cells as a protein complex
2009  529
Human prostate cancer; LNCaPFoscan/FospegNo dark toxicity with Foscan or Fospeg
Fospeg more effective: Fospeg: LD50 0.15 μg mL−1, λ = 652 nm, 180 mJ cm−2
Foscan: LD50 1.2 μg mL−1, λ = 652 nm, 180 mJ cm−2
2009  484
Macrophage-like; J774 cellsmTHPC encapsulated in nanocarriersReduced uptake but only small effect on phototoxicity and more localized pattern in cells2000  488
Mouse colon carcinoma; Colo26mTHPBC: Uptake and stabilityPartial oxidation of mTHPBC to mTHPC1997  492
Mouse mammary carcinoma, EMT-6mTHPP nanoparticles: Uptake and localizationHigher intracellular accumulation of PS with nanoparticles2003522,523
Murine glioblastoma cells; C6mTHPC liposomal formulationsCationic liposomes increase uptake2007  509
Murine leukemic cells; L1210Pharmcokinetics of mTHPC-MDMaximum fluorescence after 3 h1997  470
Murine leukemic cells; L1210mTHPC liposomal formulation with Gemini surfactantsStereochemistry of gemini spacer affects drug uptake efficiency2010  570
Murine macrophages J774.1Calcium phosphate nanoparticles with mTHPCGood PDT effect2010  450
Rabbit synoviocytes HIG-82Calcium phosphate nanoparticles with mTHPCGood PDT effect2010  450
Staphylococcus aureus; MRSA 110Liposomal formulations, antibacterial PDTMethicillin-resistant Staphylococcus aureus bacterial strain (MRSA similar to free drug2008  449
Staphylococcus aureusFospeg, antibacterial PDT4–5 log reduction in bacterial count2010  453
Human abdominal skin; mounted in Franz cellmTHPC containing flexosomesCationic flexosomes give best skin penetration and long-term stability2010  520
Synoviocytes; HIG-82mTHPP in calcium phosphate nanoparticlesUp to 87% photocytotoxicity2009  451
Macrophage cell line; J774A.1mTHPP in calcium phosphate nanoparticlesDark toxicity2009  451
Staphylococcus aureusmTHPP in calcium phosphate nanoparticlesUp to 87% photocytotoxicity2009  451
Pseudomonas aeruginosamTHPP in calcium phosphate nanoparticlesGood photocytotoxicity only with positively charged nanoparticles2009  451

Many of the studies made comparisons of the PDT efficacy between free mTHPC and mTHPC-PEG. However, which one prevails as the more efficient PDT photosensitizer is dependent upon the site of the tumor, linker groups (251,469,473) and the conditions employed for the study (252). A study with SCC cells yielded similar PDT effects for mTHPC and mTHPC-PEG and at lower light intensities mTHPC was shown to be 20 times more effective. However, mTHPC-PEG showed higher tumor accumulation rates (477). The photodynamic effect of mTHPC-MD2000 is dependent on the light protocol, as was observed for mTHPC. Similar to the situation for mTHPC the photodynamic effect of mTHPC-MD2000 is dependent on the light protocol used (153). For example, studies with interthoracic tissue of minipigs showed that while mTHPC resulted in damage to almost all tissues except nerves at short drug-light intervals, mTHPC-PEG showed no obvious damage to any tissues at any drug-light intervals (257,470) and was considered a safe drug for further applications in PDT (576). An endobronchial PDT study in minipigs showed that mTHPC under standard conditions resulted in ulceration and bronchial mucosa necrosis while mTHPC-PEG gave no such effect (471). Similarly, good results were obtained in testing the feasibility of extrapleural pneumonectomy followed by mTHPC-MD2000 PDT. No adverse side-effects were observed (482). Other animal tests included SCC (251,471,475) and adenocarcinoma xenografts (471,475), where mTHPC-PEG led to larger tumor necrosis than mTHPC in the former but not in the latter. Rabbits inoculated with cottontail rabbit papilloma virus served as another test case and gave a 58% cure rate with high drug doses. Skin tolerance was excellent in the rabbit model and in a healthy dog larynx model (485). For human oral SCC xenografts mTHPC was found to be superior to mTHPC-PEG (252). The action of mTHPC-MD5000 is delayed compared to mTHPC, but significantly exceeds that of the latter at Day 4 (475).

In human colon carcinoma xenografts the pegylated form gave on average a two-fold higher tumor uptake than free mTHPC and, at early times after injection, showed a two-fold longer blood circulating half-life and a four-fold lower liver uptake (472). mTHPC-MD5000 was preferentially localized near the tumor vessels while mTHPC was distributed more diffusely in the tumor tissue. Maximum fluorescence in this system was observed after 24 h with adequate tumor:skin (2.95) and tumor:muscle (6.61) ratios (470). Human malignant mesothelioma implanted in mice showed a similar PDT response for mTHPC and mTHPC-MD2000 but lower skin phototoxicity for the latter (486). Other studies focused on side-effects (476) or the preparation of (487) and incorporation into nanocapsules (481,488). Alternative developments for drug delivery are liposomal pegylated formulations (Fospeg) that have been used in studies on SCC (291) or mTHPC incorporated into liposomes (Foslip) (287). All three were compared for their effect to occlude neovascularization and it showed that Fospeg was the superior of the three (287). Multiphoton excitation of pegylated derivatives has been studied (479,480) and the antibacterial action of Fospeg was shown (453). More detailed biochemical studies on the intracellular effects of pegylated compounds are slowly emerging (489).

Related hydroporphyrins

In line with other PS further reduction of the mTHPC (a chlorin) will yield the related bacteriochlorin (mTHPBC) 3 with redshifted absorption spectrum (735 nm) (29). Its photophysical properties were described by Bonnett et al. (50). This bacteriochlorin undergoes photobleaching at ca 20 times the rate of mTHPC (490). It also suffers partial phototransformation to mTHPC in buffer solution (491) and can form other photoproducts as well (72). Initial tests with a mouse colon cancer cell line indicated that mTHPBC is prone to aggregation and oxidation in aqueous media (492). The cell tests showed a similar uptake profile for mTHPBC and mTHPC and identified several “forms” of mTHPBC in the cells. About 30% of the bacteriochlorins was oxidized to mTHPC in the cell within 24 h; after that its oxidation level remained stable. Initial PDT studies showed that mTHPBC has ca 60–70% of the activity of mTHPC. Its pharmacokinetics were determined in a rat colon tumor model and showed that the PDT threshold depends mainly on the administered drug dose (490). Necrosis of normal rat liver tissue was enhanced in IPDT compared to Temoporfin or Photofrin (493). Overall, the increased lability of the compound and only minor advantages suggest that this dye might not be worth further development.

Nanomedical advances

Nowadays “nano” is often considered the savior of everything that is wrong in medicine and science and PDT is no exception. In the early years of PS development this mainly meant the preparation of nanodelivery vehicles, i.e. liposomes. Naturally, there are many different means by which a “nano” approach can be used in PDT. Many reviews on the use of “nano PDT” have been published in recent years and give a good overview of the field (146,147) and about potential carrier systems (494). Others addressed more specific aspects such as quantum dots or nanoparticles (495), liposomal formulations (496), skin permeation (497) or dendritic micelles (498). There are many reasons for using nanosized materials in PDT. Perhaps the most basic is to improve the tumor selectivity through limiting the reticuloendothelial system uptake, i.e. letting “size” dictate the localization of the drug. Longer retention times of the drugs, although counterintuitively with regard to photosensitivity, also allows multiple illuminations and such can overcome the problem of oxygen depletion in the tissue.

Liposomal formulations.  Similar to the development of Fospeg® in parallel to Foscan liposomal formulations of mTHPC (some under the trademark Foslip®) have progressed well. Foslip® is a recently designed third-generation photosensitizer based on unilamellar dipalmitoylphosphatidylcholine/dipalmitoylphosphatidylglycerol (DPPC/DPPG) liposomal formulations of mTHPC. By now many applications of liposomal formulations have been tested and overall indicated reasonable utility. For example, studies with feline SCC indicated a 2-4 times better bioavailability, a shorter distribution half-life, and good selectivity compared to mTHPC (291). Detailed studies on the exact physicochemical composition of such systems are still rare (499). Fluorescence lifetime measurements indicate that Foslip and Foscan are taken up in a similar manner, but might be located in different intracellular sites (103). Incorporation into liposomes clearly changes the properties of Temoporfin (500). For example, a comparison of three chlorins, including mTHPC, in solution and incorporated in dioleoyl-sn-phosphatidylcholine liposomes showed that the three PS had a similar propensity to generate singlet oxygen in solution. However, incorporation into liposomes gave a higher efficacy for mTHPC. This was attributed to the relative distance of the PS to the water-lipid interface (501). The spectral properties significantly depend on the liposomal composition. Fluorescence measurements in DPPC liposomes with different DPPC:mTHPC ratios demonstrated a dramatic decrease in fluorescence anisotropy with increasing local drug concentration. This indicates significant interactions between the PS molecules in the lipid bulk medium. Illumination with small light doses resulted in a drop in fluorescence which could be restored through addition of Triton X-100. This photoinduced fluorescence quenching depended on the DPPC/PS ratio. Likewise, addition of plasma protein to liposomal solutions resulted in a slow redistribution of the drug to proteins (502). Thus any Foslip biodistribution analysis must take this effect into account.

Tests with mouse mammary carcinoma showed that Foslip is taken up over the course of about 1 day. Optimum but partial cure rates were observed 24 h postinjection. Fluorescence was weak and inhomogenous during the initial times and became maximal at 24 h. This might be an indication that during the initial times the fluorescence is quenched (as the drug is still in the liposomes) and that a slow release to membranes occurs. The total amount of drug present was lower compared to systemic administration, probably due to reabsorption into the blood (503). Biliary cancer cell lines reacted similarly to Foscan and Foslip, both gave excellent phototoxicity (232). Taking the water solubility and thus easier administration of Foslip into account this indicates the utility of the latter. Foslip was first tested in an animal model in 2007. Pharmacokinetic studies with a HT29 mice model showed rapid take up and good selectivity for tumor/muscle, slightly higher than that for Foscan (504). The tumor/muscle selectivity was not time dependent; however, the tumor/internal organ selectivity increased at later times. The plasma concentration was low and did not change much after PS injection. Thus, Foslip undergoes a rapid biodistribution and clearance (505). Studies in EMT6 xenografted nude mice indicated the highest tumor to muscle ratios to be reached at 6 and 15 h postadministration. The best tumor response was obtained for a drug-light interval of 6 h. At that time the drug was present in both endothelial and parenchyma cells. Nevertheless, the tumor and plasma concentrations were much lower than the maximal values (506).

A detailed analysis of the preparation of liposomal mTHPC formulations incorporated into liposomes indicated that Foslip shows promise for the treatment of age-related macular degeneration (287). Foslip has also undergone initial tests for veterinary applications in cat SCC (292). A liposomal preparation of Foscan has also been used for the treatment of cellulitis. It was applied using a mesotherapy gun-followed illumination with visible laser light with a wavelength of 652 nm and at a light dose of 10 J cm−2. Improvements of the skin thermographic pattern, of the superficial capillary net and of clinical aspects of the skin cutaneous surface were noted. However, the mechanism of action was attributed to a purely thermal effect (507). Another means to increase the uptake of Temoporfin formulations is the use of liposomes containing ethanol. Liposomes containing 20% ethanol were shown to exhibit increased skin penetration (508). Another study of liposomal systems was performed by Molinari et al. (509). Cationic liposomes with cationic Gemini 1 surfactant were found to transfer mTHPC more effectively into glioblastoma cells (510), increased its photocytotoxic effect and appeared to work in an early phase of the interaction with cells. For a general review on the current use of Gemini surfactants see Bombelli et al. (511).

Topical applications became quickly a focus of attention as well (512). A topical application of liposomal Temoporfin formulations has been tested with nonpigmented skin malignancies in humans, too. It exhibited high tumor selectivity and gave indication of a photometabolization process with a delay time of ca 30 min. No pain occurred and no swollen tissue or skin reddening (as often with ALA) was observed (513). Recently attention has focused on liposomal hydrogel formulations. A gel containing 0.75% (wt/wt) carbomer and lecithin with high phosphatidylcholine content was considered to be the optimal formulation. It delivered high amounts of mTHPC to the stratum corneum and deeper skin layers, and possessed desirable rheological properties (514). Such hydrogels were shown to exhibit good stability over a period of 6 months (515).

Another new development is the use of so-called invasosomes (516). These are phospholipid vesicles which contain a mixture of terpenes (e.g. cineole, citral or d-limone) as penetration enhancers. A first study for the use of such systems for the topical treatment of HT29 tumors in mice showed a slowed tumor growth in the treated animals (517). Initial tests showed enhanced deposition in human skin with these formulations (518,519). Flexosomes is another name recently coined for a special type of liposomes. It refers to flexible liposomes which are constructed using phosphatidylcholine plus polysorbate 20 (neutral), or dicetyl phosphate (anionic) or stearylamine (cationic) (520). Human abdominal skin was mounted in a Franz diffusion cell as a model for percutaneous penetration and treated with the respective mTHPC liposomal (or flexosomal) formulation. The anionic flexosomes were found to show insufficient long-term stability. Both neutral and cationic were stable over 9 months and the cationic flexosomes showed the highest penetration enhancing ability.

mTHPC nanoparticles.  Other attempts to prepare mTHPC containing nanoparticles focused mainly on biodegradable systems (521). A study of mTHPC encapsulated in poly(d,l lactic acid) or grafted with polyethylene glycol showed a reduced cellular uptake in HT29 tumor cells. However, the PDT effect was affected much less and the localization pattern was different to standard use (488). Other modifications resulted in significant modifications of the biodistribution and tumor retention and reduced liver uptake (481). Similar studies have been performed for related porphyrin systems (522,523). For example, a study of mTHPP encapsulated into polymeric biodegradable poly(d,l-lactide-co-glycolide) nanoparticles enhanced its photodynamic activity against mammary tumor cells when compared to the free drug (524). A recent study investigated the effect of loading mTHPP or mTHPC onto human serum albumin nanoparticles (525). Both the singlet oxygen production and the phototoxicity of the nanoformulation were increased compared to the free drugs (526).

Other possibilities are the use of quantum dots to increasing the PDT efficiency through electron transfer (527). Silica nanoparticles have been employed as well. To highlight a possible way to circumvent its low water solubility and the problems of localization, Yan et al. chemisorbed mTHPC onto nanoparticle platforms of silica as a potential drug delivery technique (528). According to singlet oxygen studies, the 1O2 production of mTHPC embedded on silica nanoparticles was higher than that of free mTHPC. But “nano” is not necessarily better. For example, mTHPC entrapped in organic-modified silica nanoparticles showed 50% less cellular uptake than the “free” drug (529). The nanoparticles underwent aggregation under high salt conditions, which could be prevented by BSA. Fluorescence resonance energy transfer experiments in esophageal cancer cells showed that the drug is transferred from the NP to serum proteins and is then internalized by the cells as a protein complex.

Micellar systems have been employed as well. For example, the water solubility of the hydrophobic 5,10,15,20-tetrakis(4-hydroxyphenyl)porphyrin could be increased by a factor of 200 through incorporation into micelles formed from hexyl-substituted polylactides in combination with PEG to give amphiphilic block copolymers PEG-hexPLA (530). Another study investigated the uptake of mTHPC loaded micelles of mPEG750-b-oligo(ε-caprolactone)5 (mPEG750-b-OCL5) with a hydroxyl, benzoyl or naphthoyl end groups (531). Micelles with benzoyl and naphthoyl end groups had the highest loading capacity. However, while they were taken up no PDT effect was observed in H&N SCC cells. Cellular uptake and photocytotoxicity was observed only in the presence of lipases, which catalyze micelle degradation. This suggests that intact micelles are not taken up by the cells. Micelles formed from poly(2-ethyl-2-oxazoline)-b-poly(d,l-lactide) (PEOz-b-PLA) diblock copolymer and loaded with Temoporfin gave a similar PDT effect in HT29 mice but resulted in less skin phototoxicity (532). Similarly, mTHPP filled PEG-PLA micelles were photoactive against H&N cells (533).

An example for a pH sensitive nanosystem was given by Peng et al. (534). They prepared Temoporfin loaded poly(ethylene glycol) methacrylate-co-2-(diisopropylamino)ethyl methacrylate (PEGMA-co-DPA) nanoparticles (89% encapsulation efficiency) and showed a faster release at pH 5 in HT29 cells compared to pH 7. Other applications used Temoporfin loaded calcium phosphate nanoparticles for antibacterial studies (535). Another possibility is the use of magnetic nanoparticles. This allows the combination of PDT with magnetic hypothermia therapy. The preparation of a magnetic nanoemulsion of Foscan showed improved skin permeability and longer skin retention times in pig ears compared to standard formulations (464). Gold nanoparticles have been loaded with three layers of mTHPP indicating the high loading capacity of such systems (536). Nevertheless, the biological utility of such systems remains unclear. Despite the current interest in nanoparticles for PDT drug delivery it is often difficult to predict the drug release from the nanoparticles in vitro or in vivo. Here, mTHPC was used to develop a flow cytometry method that allows an investigation of the transfer of dyes from donor particles to acceptor emulsion droplets (537).

Conclusions and outlook

Comparison with other PS

Surely the questions arises how mTHPC and its formulations and developments relate to other PS. However, a simple, clear cut answer is not possible. Drug development is driven by individual groups and companies, each of which may focus on different disease types, cell lines, animal models and so forth. Even at the in vitro level only few studies compare all the currently used PS (538). One example of such a study was recently presented by Berlanda et al. (539). A comparison of the six most widely used PS clearly showed the utility of both Foscan and Fospeg. Both exhibited the lowest LD50 values; however, the respective IC50 values were higher than those of the other PS. Overall, significant differences were found between the various PS. Clearly this indicates the problem involved in choosing the right (or best) PS for a given clinical application and the need for more comparative analyses at all levels. Another problem is that the patient numbers in clinical trials are still very limited in PDT and that in most cases a clinical trial focuses on one drug and not a comparison of different PS (540). Probably, a critical meta-analysis of the various PS is needed from the clinical community. Foscan’s simple preparation and purity probably makes it a better choice than the first-generation PS Photofrin. Within the range of second-generation PS questions such as type of cancer, possibility of topical application, formulations, etc., need to be taken into account.

Future developments

From a chemical viewpoint, the substitution pattern of hydroxyphenyl groups seems to be important for the exceptional photoactivity, but the molecule has an overall symmetric structure which is to some extent an antagonism to the known potential of amphilicity within PS. Unsymmetrically substituted drugs are believed to possess enhanced abilities toward the hydrophilic/hydrophobic interfaces of membranes and proteins and thus appear to be of greater photodynamic importance (541,542). Hence, a concept to screen for improved drugs is to synthetically achieve a clearly laid out library of related unsymmetrical tetrapyrroles substituted with the crucial hydroxyphenyl- or related hydrophilic groups and various hydrophobic groups, e.g. based on the ABCD-type derivatives, which are now synthetically possible (543,544). Clearly formulation studies will feature prominently in new advances and offer cheaper developmental pathways for the pharmaceutical industry. Thus, it might be worthwhile to study Temoporfin formulations with respect to delivery advances made for other PS. One example is the recent report on the use of micelle encapsulated Hp as a pulmonary delivery platform (545).

Different excitation methods can also enhance the PS effectivity. An initial study has shown that it is possible to use two-photon absorption for mTHPC PDT (546). Here, significant potential exists for the construction of appropriately designed “Temoporfin-based” two-photon absorbers (547). Possibilities also exist to improve PDT in general through different light administration (136), e.g. through saturation of the PS triplet state (548). Likewise significant potential for cost savings and safety exist through novel light sources (549). Thus, light emitting diodes have been tested in conjunction with Foscan and showed similar PDT effects in cell tests and rat liver necrosis (550,551). Optimized analysis for PDT requires multivariant analysis and not only checking on light dose, dark–light interval, and so on (552). Likewise, improvements in in vivo quantification are necessary (553). An integrated approach using real-time dosimetry and treatment planning is required and needs to be combined with multimodality imaging and PS development (554).

Many new concepts for PS delivery and action have been developed in recent years. One example is photochemical internalization (PCI) (555,556). This technique utilizes the accumulation of a drug in endocytotic vesicles which, upon light exposure, release the PS into the cytosol in active form. With regards to PS, the best candidates appear to be amphiphilic ones, and most of the initial studies focused on anionic PS. For example, the related mTHPP did not show any PCI effect (557). Still, appropriate functionalization of the mTHPC framework is chemically possible and might lead to new candidates. Not everything that is described as a new concept or has been given a catchy new name is really novel. Biological photoinactivation is one of the oldest concepts in photomedicine and thus has led the groundwork for many areas of research that currently attract interest. For example, theranostics has been coined as a term for the combined use of therapy and diagnostics in personalized medicine (558). Clearly PDT and PDD are classic examples for this, especially when combined with the need for individualized dosimetry.

Many areas of PDT have only just begun to show its potential. For example, immunostimulation offers significant potential but lacks large scale studies (208). For example, it is yet unclear whether a PDT treatment protocol to elicit local tumor control is different from that for immune stimulation. Translation studies in the latter area are clearly needed to test the utility (or lack thereof) of PDT-induced antitumor immunity. In the context of hydrophobic PS such as Foscan this also requires addressing the intracellular bioavailability of the PS (160). Still, many of the currently investigated “new” applications might look very old and go back to the beginning of photomedicine (559). Due to the high costs of drug development companies and researcher might focus more on infection, sterilization, where regulatory approval might be easier.

Several of these topics listed above are now actively investigated for various third-generation PS (560). The future will show what this ongoing process is able to deliver for the patients. At present, despite the many advances made in research and preclinical studies the translational status of PDT remains disappointing. After 40 years of studies its full clinical potential as an alternative or adjuvant therapy next to chemo and radiotherapy and surgery has not been realized. In 2006 only six PDT drugs were marketed for various indications, all with clear cost efficiency compared to classical procedures (561). The technique is easily handled, requires only minimum investments and can be performed in simple medical settings allowing use in developing countries. Many general practitioners remain unaware of this technique. Marketing appears to be especially poor and, outside of dedicated PDT centers, this modality often has the status of a niche development in oncology. In a sense its development is reminiscent of the early decades of radiotherapy development (562).

The one drawback of PDT, photosensitivity, is much relieved with newer drugs, yet more approvals are not forthcoming. There also seems to be an overemphasis on photosensitivity. Compared to other techniques this is a small price to pay for a potential cancer cure. An obvious problem with Foscan is that, while approval was granted in the EU none was given by the FDA for the United States which limits further research (563). Large scale follow-up studies remain few and most clinical uses still utilize Photofrin despite some of its drawbacks. To date the field is dominated by very few relatively small pharmaceutical companies and is driven forward mainly by dedicated clinicians and research scientists with limited financial resources. Within their hands lies the potential to use the lessons learned from second-generation PS such as mTHPC and to develop photoactive drugs that will find more general acceptance and use. While the future might not necessarily be in Foscan or its follow-ups, the use of PDT and PD in oncology has to be considered as one of the more fundamentally new treatment options in past decades (294,564).

Acknowledgement— This work was supported by grants from Science Foundation Ireland (SFI Research Professorship 04/RP1/B482, P.I. 09/IN.1/B2650) and the Health Research Board (HRB Translational Research Award 2007 TRA/2007/11).

Appendix

Author biographies

  • image

[ Mathias O. Senge ]

Mathias O. Senge, born in Silbach, Germany (1961), studied chemistry and biochemistry in Freiburg, Amherst, Marburg and Lincoln and graduated as Diplom-Chemiker from the Philipps Universität Marburg in 1986. After a Ph.D. thesis in plant biochemistry with Prof. Horst Senger in Marburg (1989) and a postdoctoral fellowship with Prof. Kevin M. Smith at UC Davis, he moved to the Freie Universität Berlin and received his habilitation in Organic Chemistry in 1996. From 1996 on he was a Heisenberg fellow at the Freie Universität Berlin and UC Davis and held visiting professorships in Greifswald and Potsdam. In 2002 he was appointed Professor of Organic Chemistry at the Universität Potsdam and since 2005 holds the Chair of Organic Chemistry at Trinity College Dublin. He was the recipient of fellowships from the Studienstiftung des Deutschen Volkes and the Deutsche Forschungsgemeinschaft; from 2005 to 2009 he was a Science Foundation Ireland Research Professor. His main interests are synthetic organic chemistry, the chemistry and biochemistry of tetrapyrroles, photosynthesis and global photobiology, the application and history of photomedicine, crystallography and structural chemistry and medicinal and bioorganic chemistry.

  • image

[ Johan Brandt ]

Johan Brandt was born in Berlin, Germany. He attended the Free University Berlin and received his degree in organic and analytical chemistry in 2004 under the guidance of Professor G. Buntkowsky. In 2005, he worked with Prof. Mathias Senge in the SFI Tetrapyrrole Laboratory at Trinity College Dublin on the development of unsymmetrical, water-soluble photosensitizers. From 2006 to 2010 he was a postgraduate student in Professor Thomas Wirth’s group at Cardiff University. Here his research interests were focussed on enabling dangerous reaction protocols in microflow systems. Since 2010 he has been pursuing an industrial career in the field of medical information.